

Innate immunity in cystic fibrosis lung disease.

AUTHOR(S)

Dominik Hartl, Amit Gaggar, Emanuela Bruscia, Andreas Hector, Veronica Marcos, Aandreas Jung, Catherine M. Greene, Noel G. McElvaney, Marcus Mall, Gerd Döring

CITATION

Hartl, Dominik; Gaggar, Amit; Bruscia, Emanuela; Hector, Andreas; Marcos, Veronica; Jung, Aandreas; et al. (2012): Innate immunity in cystic fibrosis lung disease.. figshare. Journal contribution.
<https://hdl.handle.net/10779/rcsi.10784063.v1>

HANDLE

[10779/rcsi.10784063.v1](https://hdl.handle.net/10779/rcsi.10784063.v1)

LICENCE

CC BY-NC-SA 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/Innate_immunity_in_cystic_fibrosis_lung_disease_/10784063/1

Elsevier Editorial System(tm) for Journal of Cystic Fibrosis
Manuscript Draft

Manuscript Number: JCF-D-12-00102R1

Title: Innate immunity in cystic fibrosis lung disease

Article Type: Review

Keywords: Cystic fibrosis, lung disease, bacteria, immunity, innate immunity, pattern recognition, host defense, chemokines, Toll-like receptors, neutrophils, macrophages, IL-17, PGP, chemokines, Pseudomonas

Corresponding Author: Dr. Dominik Hartl,

Corresponding Author's Institution: Infectious diseases & Immunology

First Author: Dominik Hartl

Order of Authors: Dominik Hartl; Amit Gaggar; Emanuela Bruscia; Andreas Hector; Veronica Marcos; Andreas Jung; Catherine Greene; Gerry McElvaney; Marcus Mall; Gerd Döring

Abstract: Chronic lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients. The pulmonary immune response in CF is characterized by an early and non-resolving activation of the innate immune system, which is dysregulated at several levels. Here we provide a comprehensive overview of innate immunity in CF lung disease, involving (i) epithelial dysfunction, (ii) pathogen sensing, (iii) leukocyte recruitment, (iv) phagocyte impairment, (v) mechanisms linking innate and adaptive immunity and (iv) the potential clinical relevance. Dissecting the complex network of innate immune regulation and associated pro-inflammatory cascades in CF lung disease may pave the way for novel immune-targeted therapies in CF and other chronic infective lung diseases.

Hartl et al.

Innate immunity in cystic fibrosis lung disease

D. Hartl¹, A. Gaggar², E. Bruscia³, A. Hector¹, V. Marcos⁴, A. Jung⁵, C. Greene⁶, G. McElvaney⁶, M. Mall⁷, G. Döring⁸

¹Department of Pediatrics I, University of Tübingen, Tübingen, Germany

²Departments of Medicine and Physiology/Biophysics, University of Alabama at Birmingham, Birmingham, AL, USA

³Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA

⁴Department of Pediatrics, University of Munich, Munich, Germany

⁵Department of Respiratory Medicine, University Children's Hospital, Zurich, Switzerland

⁶Respiratory Research Division, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Republic of Ireland

⁷Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics III, University of Heidelberg, Heidelberg, Germany.

⁸Medical Microbiology, University of Tübingen, Tübingen, Germany

Correspondence:

Prof. Dr. D. Hartl

Professor for Pediatric Infectiology & Immunology

Department of Pediatrics I

University of Tübingen

Tübingen, Germany

e-mail: dominik.hartl@med.uni-tuebingen.de

Running head: Innate Immunity in cystic fibrosis lung disease

1
2 Keywords: Cystic fibrosis, lung disease, bacteria, immunity, innate immunity, pattern
3
4 recognition, host defense, chemokines, Toll-like receptors, neutrophils, macrophages,
5
6 phagocytosis, migration, IL-17, PGP, chemokines, *Pseudomonas*
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

1
2 Chronic lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients.
3
4 The pulmonary immune response in CF is characterized by an early and non-resolving
5
6 activation of the innate immune system, which is dysregulated at several levels. Here we
7
8
9 provide a comprehensive overview of innate immunity in CF lung disease, involving (i)
10
11 epithelial dysfunction, (ii) pathogen sensing, (iii) leukocyte recruitment, (iv) phagocyte
12
13 impairment, (v) mechanisms linking innate and adaptive immunity and (iv) the potential
14
15 clinical relevance. Dissecting the complex network of innate immune regulation and
16
17 associated pro-inflammatory cascades in CF lung disease may pave the way for novel
18
19 immune-targeted therapies in CF and other chronic infective lung diseases.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

i. Epithelial dysfunction drives airway inflammation in CF

1
2 Mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene cause a
3
4 critical impairment of innate host defense systems in the lungs of cystic fibrosis (CF) patients.
5
6 This results in an early and severe form of chronic airways disease, featuring mucus
7
8 obstruction, neutrophil-dominated airway inflammation and bacterial infection, finally leading
9
10 to progressive pulmonary damage with bronchiectasis and emphysema¹⁻⁴.
11
12

13
14 The airways are lined by an epithelial layer that integrates several functions important
15
16 for effective defense against inhaled pathogens and other noxious agents, ranging from a
17
18 barrier function, proper surface hydration by regulated transport of ions and fluid, mucus
19
20 secretion, and mucociliary clearance^{5,6} to expression of antimicrobial peptides⁷, receptors that
21
22 recognize pathogens associated molecular patterns (PAMPs) and host-derived danger signals
23
24 (DAMPs) and the secretion of chemokines and cytokines that orchestrate the recruitment of
25
26 leucocytes⁸ as well as the local immune responses in the airway lumen⁹. Given this broad
27
28 functionality of the airway epithelium in innate lung defense, and the fact that the *CFTR*
29
30 protein is expressed in the apical membrane of the surface epithelium and in submucosal
31
32 glands^{10,11}, the link between epithelial *CFTR* dysfunction and the pathogenesis of CF airways
33
34 disease has long been in the focus of CF research.
35
36
37
38
39
40

41 In healthy airways, *CFTR* acts as a cAMP-dependent Cl⁻ channel^{12,13} that works in
42
43 concert with the Ca²⁺-activated Cl⁻ channel (CaCC)¹⁴ to secrete Cl⁻ and fluid required for
44
45 hydration of mucins and other secreted molecules that form airway mucus. In the surface
46
47 epithelium, *CFTR* also functions as regulator of the amiloride-sensitive epithelial Na⁺ channel
48
49 (ENaC) that constitutes the limiting pathway for Na⁺ and fluid absorption¹⁵. Given this dual
50
51 functionality in vectorial ion transport, *CFTR* plays a key role in coordinate regulation of
52
53 secretion and absorption of NaCl and fluid, and hence airway surface liquid (ASL)
54
55 homeostasis^{6,16}. Accordingly, in CF airways, epithelial *CFTR* dysfunction results in an
56
57 imbalance between Cl⁻ secretion and ENaC-mediated Na⁺ absorption rendering the airways
58
59
60
61
62
63
64
65

1 surfaces vulnerable to ASL volume depletion. In a series of studies using highly-differentiated
2 primary airway cultures it was shown that airway surface dehydration impaired ciliary beating
3 and mucus transport, and promoted mucus stasis and adhesion in CF airway epithelia^{17,18}.
4 Since mucociliary clearance acts as an important integral part of the innate pulmonary defense
5 system, these results indicated that mucociliary dysfunction due to airway surface dehydration
6 constitutes a disease-causing mechanism that links the basic CF defect to impaired airways
7 defense and CF lung disease. The *in vivo* evaluation of the “dehydration hypothesis” was
8 hampered for a long time by the fact that *Cftr*-deficient mice did neither show abnormal Cl⁻ or
9 Na⁺ transport in their lower airways, nor develop CF-like lung disease¹⁹⁻²³. This limitation
10 was overcome in a mouse model with airway-specific overexpression of the β subunit of
11 ENaC (β ENaC) developed to mimic increased Na⁺ absorption characteristic of CF
12 airways^{19,24}. In this model, an imbalance between Cl⁻ secretion and Na⁺ absorption caused
13 ASL depletion and reduced mucus clearance *in vivo*, and resulted in a lung disease that shares
14 many features of early lung disease in CF patients, including airway mucus obstruction,
15 reduced bacterial clearance, chronic neutrophilic inflammation and emphysema, supporting
16 the notion that epithelial impairment initiates and sustains inflammation^{19,24,25}. Further,
17 studies in β ENaC-overexpressing mice demonstrated that preventive pharmacological
18 targeting of ASL depletion by the ENaC inhibitor amiloride has substantial therapeutic effects
19 on CF-like mucus obstruction and airway inflammation²⁶. These results validated impaired
20 ASL homeostasis resulting from a basic epithelial ion transport defect in CF airways as a
21 disease-initiating mechanism in the *in vivo* pathogenesis and as a therapeutic target of CF lung
22 disease. Hence, the β ENaC-overexpressing mouse will also provide opportunities for further
23 *in vivo* elucidation of the molecular mechanisms underlying the initiation and perpetuation of
24 dehydration-induced airway inflammation, and its contribution to impaired host defense and
25 lung damage that will be reviewed in the sections below.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

In addition to the well established impairment of epithelial ion transport, other epithelial dysfunctions have been implicated in chronic inflammation and infection of CF airways, including increased apoptosis due to accumulation of ceramide, a promising approach for drug targeting^{27,28}, intrinsic pro-inflammatory properties, exaggerated inflammatory responses to viral and bacterial infections, and reduced clearance of *Pseudomonas aeruginosa* (*P. aeruginosa*)^{29-31,32,33}. For studies indicating a link between CFTR and glutathione or Ca²⁺ channels we refer to a recent review by Ratner et al³⁴. We expect that the recent development of small-molecule CFTR modulators designed to improve impaired CFTR Cl⁻ channel function in CF^{35,36}, together with sensitive assays for quantitative assessment of mutant CFTR function in native tissues^{37,38}, will help to dissect the relative roles of the CF ion transport defect and other epithelial dysfunctions in chronic inflammation and impaired host defense in the CF lung.

ii. CF pathogens are sensed through distinct pattern recognition receptors

Infections with *Staphylococcus aureus*, *Haemophilus influenzae* and *P. aeruginosa* are mainly characteristic for CF patients. Other emerging bacterial pathogens, such as *Burkholderia cepacia* and *Stenotrophomonas maltophilia*, or fungi like *Aspergillus fumigatus*³⁹, *Candida albicans*⁴⁰ or *Scedosporium apiospermum*⁴¹ are increasingly appreciated to play a role in CF lung disease^{3,42}. Whereas *Staphylococcus aureus* and *Haemophilus influenzae* infections manifest in younger CF patients, *P. aeruginosa* is the predominant pathogen in later infancy, teenage-age and adult CF patients. Colonization with *Aspergillus* and/or *Candida spp.* is mainly found in older CF patients, but their pathophysiological relevance is poorly understood so far^{39,43,44}. Infections with *P. aeruginosa* seem to favor colonization with *Aspergillus fumigatus* and associated allergic bronchopulmonary aspergillosis (ABPA)^{39,43}, potentially due to a *P. aeruginosa*-mediated Th2 shift⁴⁵.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Given the long-term and intimate contact of pathogens with the lining CF airways, the mechanisms by which these pathogens are recognized by the host are of key relevance for the understanding of innate immunity in CF lung disease. In general, the innate immune system - senses conserved molecular patterns using pattern recognition receptors (PRR), with Toll-like receptors (TLRs) representing the prototypic PRRs^{46,47}. Other non-TLR PRRs include complement receptors, Fc receptors, nucleotide-binding oligomerization domain family (NOD)-like receptors, scavenger receptors, RIG-like helicases, nucleic acid receptors and others⁴⁸. The majority of TLRs recognize bacterial patterns (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9, TLR10, TLR11) with TLR4 sensing lipopolysaccharide (LPS), TLR5 flagellin, TLR9 CpG oligonucleotides and TLR11 uropathogenic bacteria and/or profilin from protozoa. Viral PAMPs are recognized through TLR3 (double-stranded RNA, dsRNA), TLR7 and TLR8 (single-stranded RNA, ssRNA). Beyond microbial PAMPs (recently also termed for microbes in general independent of their pathogenicity as microbe-associated molecular pattern, MAMPs), TLRs sense endogenous ligands (DAMPs), including heat shock protein 70 (HSP-70), proinflammatory extra domain A of fibrinogen, extracellular CXCR1 moieties, heparan sulfate fragments, elastase, hyaluronic acid fragments (TLR4) and others. TLRs are expressed by a variety of immune and structural cells, including monocytes/macrophages, dendritic cells, lymphocytes, endothelial cells, myocytes, epithelial cells, neutrophils and others. Here we will focus on TLRs expressed by epithelial cells, since they represent the first cellular line of pattern recognition in the CF airway microenvironment.

Airway epithelial cells including tracheal, bronchial and alveolar type II cells express a broad repertoire of TLRs^{9,49-52}. Most anti-bacterial TLRs are appropriately exposed on the mucosal surface of the airway and can be readily activated by superficial exposure to microbial factors. The predominant TLR expressed on the surface of bronchial epithelial cells *in vivo* appears to be TLR2, with other TLRs (TLR3, TLR4, TLR5) residing mainly intracellularly yet displaying low level surface expression. Whilst in macrophages and

1 dendritic cells⁵³ TLR7, TLR8 and TLR9 reside endosomes, in both immortalised and
2 differentiated primary airway epithelial cells^{54,55}, TLR9 has also been detected on the cell
3 surface expression using flow cytometry. Some TLRs can be mobilised to the airway
4 epithelial cell surface following stimulation with microbial factors. For example cell surface
5 localisation of TLR4 and TLR5 is promoted by Respiratory Syncytial Virus (RSV) infection
6 and flagellin, respectively^{56,57}, whereas infection with *P. aeruginosa* enhances TLR2
7 localisation within lipid rafts on the apical surface of airway epithelial cells⁵⁸.

17 Three early reports described TLR expression in primary and transformed CF airway
18 epithelial cells^{55,59,60}. These studies provided the first evidence that TLRs 1-10, the TLR4
19 accessory protein MD2 and the TLR adaptor protein myeloid differentiation primary response
20 gene 88 (MyD88) are expressed and functional in CF airway epithelium. As in non-CF airway
21 epithelial cells, bacterial stimulation of CF cells caused up regulation of TLR2, albeit reduced.
22 Similarly, TLR4 is displayed poorly on the apical surface in CF cells and fails to respond well
23 to stimulation with LPS. John *et al.* investigated the functional consequences of this, and
24 independently confirmed that TLR4 expression is decreased in CF bronchial epithelium
25 resulting in weaker than normal MyD88 and TRIF-dependent signalling^{61,62}, possibly leading
26 to impaired adaptive immune responses. For further detailed discussion of the role of TLRs in
27 CF airway epithelial cell responses we also refer to an recently published review⁶³.

43 TLR5 is a key TLR expressed by airway epithelial cells and can mediate inflammatory
44 responses to flagellin-expressing but not *fliC* (flagellin-deficient) mutants of *P. aeruginosa*
45 and *Burkholderia cepacia* (*B. cepacia*)⁶⁴; it represents also the predominant TLR responsible
46 for lung epithelial inflammatory responses to *B. cenocepacia*⁶⁵. In CF airway epithelial cells
47 inhibition of TLR5 can abolish IL-6 production normally generated following exposure to *P.*
48 *aeruginosa*, identifying TLR5 as a potential therapeutic target for CF lung inflammation⁶⁶.
49 Interestingly CF adults with a TLR5 1174C>T SNP, which encodes a premature stop codon in
50 TLR5 that is associated with decreased flagellin-responsiveness, appear to have improved

1 nutritional status as measured by higher body mass index⁶⁷. Thus TLR5 could also represent a
2 modifier gene for CF. However antagonism of TLR5 alone may not be sufficient to decrease
3
4 CF airway epithelial cell responses to *P. aeruginosa*. Reduced glutathione levels sensitize
5
6 these cells to the action of reactive oxygen species generated by NADPH oxidase leading to
7
8 enhanced CXCL8/IL-8 expression⁶⁸. Therefore, targeting both oxidants and TLRs, in addition
9
10 to other recently reported experimental anti-inflammatory strategies, is likely to have greater
11
12 therapeutic benefit. CF patients are commonly co-colonised with *Aspergillus* species⁶⁹.
13
14 Conidial dsRNA can induce interferon- β via activation of TLRs in non-CF airway epithelial
15
16 cells⁷⁰, however it remains to be shown whether CF airway epithelial cells respond in a
17
18 similar way or whether their response to *Aspergillus* occurs as a result of chitin-induced
19
20 activation of TLR2 as seen in murine macrophages⁷¹.
21
22
23
24
25

26 The CF lung is a MAMP/PAMP- and DAMP-rich milieu and, in addition to classical
27
28 TLR agonists, contains a selection of factors that can indirectly activate TLRs. Neutrophil
29
30 elastase activates TLR4 via a mechanism involving meprin and/or Tumor necrosis factor-
31
32 alpha-converting enzyme / a disintegrin and metalloproteinase domain 17 (TACE/ADAM17),
33
34 TGF α and EGFR⁷²⁻⁷⁵, leading to exaggerated IL-8 and mucin gene expression whilst
35
36 hemoglobin, which can be present in the fragile CF lung due to micro-bleeds, liberates free
37
38 heme as a result of cleavage by elastase and/or *P. aeruginosa*-derived proteases that can
39
40 similarly activate TLR signaling and proinflammatory gene expression via EGFR-TLR
41
42 signaling⁷⁶. Although TLR hyper-responsiveness is largely accepted to contribute to CF lung
43
44 pathology there are a number of contexts where inadequate bronchial epithelial TLR-
45
46 mediated responses can occur and are likely to impact negatively on pulmonary inflammation.
47
48 In CF females high circulating estrogen levels can impair TLR-induced NF κ B activation and
49
50 cytokine expression via estrogen-receptor- β -mediated up regulation of secretory
51
52 leucoprotease inhibitor (SLPI)⁷⁷: SLPI is an antiprotease with anti-inflammatory and
53
54 immunomodulatory properties that can prevent NF κ B activation by interfering with
55
56
57
58
59
60
61
62
63
64
65

1 proteasomal degradation of I κ B^{78,79} and by blocking p65 binding to NF κ B consensus
2 sequences in chromosomal DNA⁸⁰. This, along with other estrogen-induced effects, likely
3 contributes to the gender gap in CF whereby CF females have poorer lung function, worse
4 exacerbations and convert to mucoid strains of *P. aeruginosa* prematurely compared to males.
5
6

7
8
9 Altered microRNA expression in CF bronchial epithelium *in vivo* can also impact on
10 TLR signalling potentially leading to TLR hypo-responsiveness⁸¹. Decreased miR-126
11 controls reciprocal increases in TOM1 which can interfere with TLR2 and TLR4 responses
12 and may also contribute to CF-specific decreased cell surface expression of TLR4. These
13 subtle regulatory mechanisms underscore the importance of carefully considering the context
14 and timing in which future TLR-directed therapies should be prescribed.
15
16
17
18
19
20
21
22
23
24
25

26 **iii. Chemokines and extracellular matrix break-down products orchestrate the** 27 **recruitment of leukocytes into CF airways**

28
29 **As consequence of epithelial dysfunction and pathogen sensing, a pro-inflammatory cascade**
30 **is initiated in CF airways that leads to the recruitment of leukocytes from the bone-marrow**
31 **niche via the circulation into the airways.** While professional phagocytes, such as
32 macrophages and microphages (neutrophils), are essential in clearing the lungs from bacterial
33 and fungal pathogens, their uncontrolled action in the absence of microbial threat causes
34 tissue damage and tissue remodelling. Therefore, the in-depth understanding of mechanisms
35 driving leukocyte migration into CF airways under infectious and non-infectious conditions is
36 pivotal for future therapeutic approaches targeting specific, host-damaging recruitment
37 pathways, while preserving antimicrobial host defense capacities.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 Our current view of leukocyte migration in chronic neutrophilic inflammation
54 becomes increasingly complex and has overcome the traditional concept that single disease-
55 associated chemoattractants direct leukocyte migration into tissues. Leukocytes
56 transmigration into the extravascular space represents a multi-step process, involving rolling,
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
activation, adhesion and diapedesis, requiring the concerted action of integrins, selectins and chemokines⁸²⁻⁸⁴. There is limited evidence for CF-associated dysregulations in the context of neutrophil transmigration. The relevant pathomechanisms seem to be complex, since CFTR neutrophil-intrinsic, airway epithelial cell-dependent and transmigratory lung epithelium feedback factors have to be considered^{85,86,87}. Related to transmigration mechanisms, dysregulations in L-selectin shedding⁸⁸, complement receptor (CD11b/CD18) expression⁸⁹ and ICAM-dependent airway epithelial cell-neutrophil interactions⁹⁰ have been described.

Tissue-released chemokines (major source: epithelial cells and macrophages) attract leukocytes via chemokine gradients to the site of inflammation, putting chemokines and their G-protein coupled receptors in the spotlight of targeted anti-inflammatory strategies⁹¹. However, the previous years have substantially extended the notion that chemokines are predominantly responsible for attracting leukocytes to diseased **organs** by demonstrating that products liberated from necrotic cells (alarmins) and tissue extracellular matrix break-down products, as discussed below in detail, are capable of initiating and sustaining leukocyte recruitment^{92,93}.

Cytokines and chemokines

Cytokines, as small molecular weight proteins, influence a plethora of biological processes including cellular activation, recruitment, cell death, and repair and play a critical role in the regulation of innate immunity in a variety of disorders including CF⁹⁴. Due to the chronic bacterial colonization of the CF airways, cytokines are continuously produced at the pulmonary site of inflammation and exert their influence in a paracrine manner at the interface of bacteria and airway epithelial cells⁹⁵. This ongoing activation of innate immune receptors by bacteria and bacteria-associated PAMPs/MAMPs leads in the CF microenvironment to the dysregulated production of cytokines; elevated levels of pro-inflammatory cytokines (such as TNF- α , IL-6, IL-1 β) and reduced levels of anti-inflammatory cytokines (such as IL-10) have been reported in the bronchoalveolar lavage (BAL) and

1 sputum of patients with CF lung disease⁹⁶. Despite general agreement about the imbalance of
2 these cytokines in the CF lung, it remains a challenge to assess how these cytokines regulate
3 biological and cellular functionalities in the CF lung.
4
5

6
7 The prototypic pro-inflammatory cytokine TNF- α is mainly released from monocytes
8 and macrophages and has pleiotropic effects central to innate immunity, including
9 inflammatory cell recruitment and induction of additional cytokines⁹⁷. TNF- α has been
10 traditionally regarded as an early release cytokine and, therefore, its persistence in the CF
11 airways strongly suggests ongoing production from both resident alveolar macrophages and
12 recruited monocytes⁹⁸. Although TNF- α is elevated in the CF lung, it has not shown a strong
13 correlation with progression of disease^{99,100}. In addition, there have been variable results in
14 the regulation of TNF- α production during pulmonary exacerbation of CF lung disease^{101,102}.
15
16 Besides TNF- α , IL-1 (both IL-1 α and IL-1 β) have been studied in the context of CF. Similar
17 to TNF- α , IL-1 β is released from macrophages/monocytes and is actively involved in
18 inflammatory cell recruitment and the amplification of the pro-inflammatory cytokine
19 response¹⁰³. Both isoforms have been found to be elevated in the blood and airway samples
20 (BAL and sputum) from CF patients^{100,104-106}. IL-1 β levels have been shown to be increased
21 both in the sputum and BAL of CF patients who were chronically colonized with *P.*
22 *aeruginosa* compared to those individuals who were not colonized¹⁰⁷. In parallel, eradication
23 of *P. aeruginosa* leads to decreased IL-1 β levels in the BAL of CF children¹⁰⁸. Despite these
24 findings, the correlation of IL-1 β with progression of disease remains poorly linked. IL-10 is
25 a critical anti-inflammatory protein capable of reducing the production of multiple pro-
26 inflammatory proteins. The levels of IL-10 have been found to be decreased in the CF lung of
27 older patients¹⁰⁷; this may in part be due to differences in secretion of IL-10 from airway
28 epithelial cells¹⁰⁹. Interestingly, younger children do not seem to exhibit differences in IL-10
29 levels between CF and non-CF individuals¹¹⁰. Due to potential differences observed of IL-10
30 in older patients, there is significant interest in directed gene therapy to restore IL-10 balance
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

in CF lung disease and preclinical studies are underway¹¹¹. The potential role of these CF-associated cytokines as disease biomarkers is reviewed in detail elsewhere¹¹². Therapeutically, anti-cytokine strategies (biologicals), which are already successfully implemented in the therapy of rheumatoid arthritis, are reasonable to consider in progressive CF lung disease. However, the increased infection susceptibility and related side effects¹¹³ have to be taken into account, in particular in older CF patients suffering from chronic bacterial infections.

A distinct subset of chemotactic cytokines, termed chemokines, orchestrates the recruitment and activation of inflammatory cells^{114,115}. Perhaps the best studied chemokine in CF lung disease is CXCL8 (IL-8). CXCL8 acts on both CXCR1 (IL-8RA, CD181) and CXCR2 (IL-8RB, CD182) surface receptors; this chemokine exhibits pleotropic effects on neutrophils, acting as a potent chemoattractant and inducing degranulation and superoxide production¹¹⁶. Many groups have reported elevated levels of this chemokine in the BAL and sputum of both CF adults and children^{107,112,117-119}. Further cellular studies demonstrated that CXCR1, but not CXCR2, is involved in antibacterial effector functionalities by neutrophils and that CXCR1 is proteolytically cleaved in CF airways, thereby disabling CXCL8-mediated enhancement of anti-bacterial effector functions¹¹⁷. There are also reports of CXCL8 levels correlating with patients' clinical status, including Schwachmann scores, bacterial colonization with *P. aeruginosa*, and lung function¹²⁰⁻¹²². **Despite these findings, studies targeting this molecule in chronic obstructive pulmonary disease (COPD), featuring a similar chronic neutrophilic lung disease, have not shown clinical benefits so far¹²³,** strongly suggesting additional, redundant chemotactic and activation pathways being important in COPD and probably CF disease pathogenesis. Other chemokines that have been studied in CF include CCL2¹²⁴, CCL3, CCL4, and CCL20¹²⁵ as well as a deficiency of the Th1- and human **Immunodeficiency Virus (HIV)-associated chemokine CCL5 (RANTES)^{126,127}.** In ABPA, the Th2-associated CC chemokines CCL17 and CCL22 have been proposed as potential biomarkers^{43,128-132}.

Proline-Glycine-Proline and high mobility group box protein-1

1
2 Beyond the canonical pathways of preformed cytokines/chemokines regulating inflammatory
3
4 response in CF, recent evidence suggests a significant noncanonical pathway responsible of
5
6 neutrophil influx. This pathway involves the coordinated cleavage of extracellular matrix
7
8 (ECM) to small fragments, capable of acting on chemokine receptors on inflammatory cells.
9
10 Although hypothesized in human disease for over 50 years, the identification of these
11
12 fragments and mechanisms related to their action was poorly understood for a long time¹³³.
13
14 Recently, however, a fragment of collagen proline-glycine-proline (PGP) has been identified
15
16 in the sputum and serum of CF patients¹³⁴. This peptide acts as a ligand mimetic for CXCR1
17
18 and CXCR2 due to similarities in the structure of ELR+ CXC chemokines. PGP (and its N-
19
20 terminal acetylated form, Ac-PGP) have been shown to induce chemotaxis, produce
21
22 superoxide, and induce release of proteases from neutrophils¹³⁵. The liberation of PGP from
23
24 collagen is a multiprotease pathway, with the initial cleavage of collagen mediated by matrix
25
26 metalloprotease (MMP)-8 and MMP-9 and subsequent cleavage conducted by prolyl
27
28 endopeptidase (PE), a serine protease first described in this work as playing a role in
29
30 pulmonary inflammation¹³⁶. Recently, a pathway regulating PGP degradation and inactivation
31
32 has been described through a novel aminopeptidase activity of the enzyme leukotrieneA4
33
34 hydrolase (LTA4H)¹³⁷. Persistence of PGP in chronic neutrophilic lung disorders has been
35
36 well-documented and PGP peptides were found to be elevated in the sputum of individuals
37
38 with CF lung disease compared to non-lung disease controls¹³⁶. At the beginning of inpatient
39
40 exacerbation, PGP peptides were increased and these peptides decreased at the end of therapy,
41
42 consistent with improvement in lung function. However, the end-of-exacerbation PGP levels
43
44 were still significantly higher than non-lung disease controls, suggesting ongoing
45
46 inflammatory response in the lung despite resolution of exacerbation. PGP peptides have also
47
48 been detected in the serum of CF patients, suggesting a possible systemic role for this peptide
49
50 in human disease; ongoing research is focusing on the variety of systemic effects of this
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

peptide in CF disease. Figure 1 illustrates the proposed mechanisms by which PGP drives and perpetuates chronic neutrophilic airway inflammation in CF.

A further host-derived inflammatory protein involved in CF lung is high mobility group box protein-1 (HMGB1). This chromatin protein is released from inflammatory cells (such as monocytes) or from necrotic cells¹³⁸ and acts intracellularly to enhance nucleoprotein interactions¹³⁹. Once released, this protein can act as a potent proinflammatory cytokine by its binding to RAGE, TLR and CXCR4 receptors^{140,141}. Recently, Rowe et al. have described the increased presence of extracellular HMGB1 levels in the secretions of CF patients and in the β ENaC mouse model¹³⁴. In addition, this elevation of HMGB1 closely correlated with the presence of the chemotactic collagen fragment PGP and offers the consideration if these pathways of inflammation are linked¹⁴².

iv. Recruited phagocytes are impaired in the CF microenvironment

Bone marrow-derived immune cells are continuously recruited to the infective pulmonary microenvironment in CF lung disease in order to clear the bronchoalveolar pathogens.

Neutrophils and macrophages are the major antibacterial effector cells, are therefore termed as 'professional phagocytes' and are here discussed in detail, while dendritic cells (DCs) phagocytose but act mainly as antigen presentators and T cell instructors to bridge innate and adaptive immunity and are only summarized briefly at the end of this paragraph, particularly regarding the paucity of data concerning DCs in CF.

Neutrophils

In healthy adults, 10^{11} neutrophils daily transit through the circulation¹⁴³. Upon infection, these neutrophils rapidly transmigrate to the site of inflammation, where they sense PAMPs and/or DAMPs and combat pathogens. Airway fluids (sputum, BALF) of CF patients contain millions of neutrophils, which led to the well-established notion that CF lung disease is dominated by a neutrophilic airway inflammation^{8,117}. In general, the pathophysiological role

1 of airway neutrophils in CF and other chronic neutrophilic lung diseases is two-faced: On the
2 one hand they are required for antibacterial and antifungal host defense, on the other hand
3 they can cause significant parenchymal lung tissue damage when they accumulate over longer
4 time periods and liberate their toxic granule contents, mainly serine and metalloproteases as
5 well as oxidants, in an uncontrolled fashion¹⁴⁴. Based on this scenario, the targeting of distinct
6 harmful subtypes of airway neutrophils, while preserving other beneficial subtypes, may
7 provide the possibility to specifically modulate the neutrophilic activity in CF lung diseases.
8

9
10
11
12
13
14
15
16
17 Regarding the role of CFTR in neutrophil homeostasis and function, studies suggest a
18 functional relevance of CFTR in regulating anti-bacterial neutrophil activities (see discussed
19 in detail below)¹⁴⁵⁻¹⁴⁷. Isolated neutrophils from CF patients were found to release more
20 elastase from primary granules than control cells¹⁴⁸ and showed enhanced migratory
21 capacities¹⁴⁹, but a blunted phagocytic capacity¹⁵⁰. On the other hand, studies indicated that
22 neutrophils from CF patients showed no difference in terms of phagocytosis (in newborns)¹⁵¹
23 or ROS generation¹⁵², suggesting that local/pulmonary factors play also a role in modulating
24 neutrophil effector functionalitis *in vivo*. This notion is supported by the finding that CF
25 sputum stimulates CD18-independent neutrophil migration across endothelial cells¹⁵³. Studies
26 analyzing cell death pathways in peripheral blood-isolated cells added another angle by
27 demonstrating that circulating neutrophils from CF patients feature a slower apoptosis
28 rate^{154,155 156,157}. When viewing these studies in combination, both systemic/CFTR-associated,
29 cell death-related as well as pulmonary factors probably contribute in the regulation of
30 neutrophil functionality in CF airways.
31

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 Regarding the usefulness of neutrophils or neutrophil-derived proteins, a large number
52 of studies investigated the relationship between neutrophil numbers, phenotypes and
53 neutrophilic mediators in CF patients and correlated them with disease outcome parameters,
54 such as pulmonary function^{32,45,112,118,130,131,158-165}. These studies provided evidence that both
55 the extent of neutrophilic airway inflammation as well as neutrophil proteins, prototypically
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

neutrophil elastase, correlate with pulmonary obstruction (FEV1) in different CF patient cohorts. A large US multicenter study compared different CF sputum markers as predictors for FEV1 decline and found that neutrophil elastase showed the highest correlation with longitudinal FEV1¹¹⁸, suggesting sputum elastase as promising biomarker for CF airway inflammation. Other studies analyzing BALF found increased elastolytic activity in a subset of CF infants very early in the course of CF lung disease¹, supporting, in line with murine β ENaC studies^{19,24}, the notion that neutrophilic-proteolytic inflammation starts early in the pathogenesis of CF lung disease. Beyond elastase, other studies found evidence for neutrophil-derived proteins as potential biomarkers in CF lung disease, in particular calprotectin^{166,167}, a S-100 protein located in specific granules, MMP9^{159,158,168} stored in tertiary granules, myeloperoxidase (MPO)¹⁶⁹ and proteinase 3^{170,171} stored in primary granules, the chitinase-like protein YKL-40¹⁶⁰ and others. In a study comparing gene expression in peripheral blood neutrophils from CF patients and healthy controls, 1050 genes were found to be upregulated¹⁷², with the majority not being studied so far in the context of CF lung disease, indicating that the field of neutrophilic inflammation in CF is complex and requires future studies to gain mechanistic insights.

Neutrophils release their granules sequentially, starting with secretory vesicles that shuttle between cytoplasmic compartments and the plasma membrane, which are pivotal for recycling and mobilization of complement-, Fc- and other receptors. Tertiary granules contain MMP-9, a marker protein involved in transmigration of neutrophils and the initiation of proteolytic extracellular matrix degradation. Upon intensified and prolonged stimulation, neutrophils liberate their secondary granules that contain anti-microbial proteins, such as lactoferrin and cathelicidine, liberated to cope with encountering pathogens. Upon direct pathogen contact, neutrophils engage their strongest granule weapon, the primary or azurophilic granules. This event liberates serine proteases that target both engulfed pathogens in the phagolysosome or, when liberated in an uncontrolled or pathogen-independent fashion,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
extracellular matrix and leukocyte surface receptors, such as the CXCL8 / IL-8 receptor
CXCR1 (CD181), T cell or complement receptors. These proteolytic effects are dependent on
the protease/anti-protease balance in the CF airway microenvironment, a comprehensive topic
by itself^{173,174}. Of note, ASL without proteolytic activity has been shown to have no major
effect on neutrophil activity *in vitro*¹⁷⁵. Given the stepwise granule release mechanism,
granule proteins detectable in CF airway fluids may represent distinct stages of neutrophil
activation. For a more in-depth review on neutrophil granules we refer to Hager et al.¹⁷⁶.
Consequently, studies investigating proteins characteristic for all four intracellular neutrophil
granule/vesicle compartments in peripheral and airway neutrophils from CF patients and
controls are warranted to understand the differential activation state of CF neutrophils
comprehensively. Furthermore, longitudinal studies analyzing neutrophil markers in CF
airway fluids are required to understand the kinetics of neutrophilic activation in CF lung
disease.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
Beyond these studies, desmosin, an urinary marker of elastin was found to be
associated with disease outcome and inflammation in CF patients^{177 29}. Recently, the
neutrophil-derived alpha-1 antitrypsin and CD16 protein heterocomplex (AAT:CD16) has
been reported as potential biomarker for exacerbations in CF¹⁷⁸. Intriguingly, Voglis et al.
showed that human neutrophil peptides impaired the phagocytic capacity of neutrophils in an
auto- and/or paracrine manner in both CF and non-CF bronchiectatic conditions¹⁷⁹.

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
In the airway microenvironment of chronic *P. aeruginosa* infections, infiltrated
neutrophils are faced with *Quorum sensing*-induced bacterial biofilms¹⁸⁰ and this interaction
substantially modulates the phagocyte's behaviour. *P. aeruginosa* can exploit the neutrophil-
derived host DNA to form biofilms¹⁸¹. In turn, CF airway fluid biofilm-associated neutrophils
have been described to be distinct in terms of impaired migration with preserved
phagocytosis¹⁸², modulated respiratory burst activity¹⁸³ and ongoing oxygen consumption¹⁸⁴.
Further interaction mechanisms between *P. aeruginosa* and neutrophils implicate TLRs, with

1
2
3
4
5
6
7
8
9
10
11
12
13
TLR5 seeming to play a major role¹⁸⁵, pyocyanin, a *P. aeruginosa*-derived exotoxin that is
capable of inducing neutrophil apoptosis¹⁸⁶, neutrophil extracellular trap (NET) formation
(NETosis)¹⁸⁷ (as discussed below in detail) and type III secretion-dependent oncosis¹⁸⁸.
Further abnormalities reported for CF neutrophils include catalase- and MPO-dependent
actions¹⁸⁹, oxidant release^{190,191,192,193}, neutrophil apoptosis¹⁵⁷, Coronin-1-associated
neutrophil survival¹⁵⁶ and others not discussed here in detail^{194, 195,87,196}.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
The phenotypical characterization of neutrophils in CF airways is hampered by several
facts: (i) heterogeneity among CF patients (extent of neutrophilic inflammation, infections),
ability to sample sputum (impeding sputum studies in CF infants younger than about 5/6 years
of age), (iii) pre-analytical processing of complex airway fluids material (sputum, see¹⁹⁷ for
details) and cleavage of surface markers essential for neutrophil subtype characterization. A
few studies used advanced optimized flow cytometric approaches to dissect airway neutrophil
subpopulations^{198,199,8,185,200}. These studies provided evidence that CF airway neutrophils
contain different subphenotypes, which feature non-canonical surface receptor expression
characteristics, in particular CXCR4, CD39, RAGE, CD114 and CCR5. The functional and
pathophysiological relevance of these CF airway-site specific neutrophil phenotypes remains
to be defined^{201,198,195}.

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Neutrophils at the pulmonary site of inflammation are instrumentalized with three
main anti-bacterial weapons: phagocytosis, granules release and NET formation²⁰², which are
employed depending on the duration and severity of host-pathogen interactions (Figure 2).
There is evidence for impaired phagocytosis¹⁵⁰ and release of protease-rich primary
granules¹⁴⁸ in CF neutrophils as discussed above and summarized in Table 1. When
neutrophils at the pulmonary site of host-pathogen interaction are unable to cope with the
encountered pathogen by phagocytosis or granule attack, they employ their final
armamentarium which is their own DNA. Upon prolonged stimulation, neutrophils release
NETs, that are DNA fibres that entangle, immobilize and kill mainly bacterial and fungal

1 pathogens. The mechanisms by which NETs kill the captured and immobilized bacteria are
2 still not fully understood, but histones and granule proteins, such as proteases and
3 calprotectin, could play a role^{203,204}. CF airway fluids feature abundant extracellular DNA²⁰⁵
4 and the amount of free extracellular DNA shows an association with pulmonary function in
5 several studies²⁰⁶⁻²⁰⁹, supporting the concept that recombinant DNases acts beneficial in CF
6 lung disease by cleaving the NET-DNA meshwork and thereby facilitating mucociliary
7 clearance of cleaved DNA strands. NETs in the CF airway context are mainly formed upon
8 contact with *P. aeruginosa* and a recent study nicely demonstrates that NETs are capable of
9 killing *P. aeruginosa* bacteria²¹⁰. The *CFTR* gene defect does not seem to affect NET-otitc
10 killing, since no difference between CF and non-CF neutrophils were found²¹⁰. Intriguingly,
11 isogenic clinical *P. aeruginosa* isolates from CF patients exhibited an acquired resistance
12 towards NET-mediated killing, which correlated with the mucoid phenotype, but was not a
13 direct result of excess alginate production²¹⁰. NET formation seems to be critically involved
14 in the host defense against other CF-associated pathogens, such as *Aspergillus fumigatus*²¹¹
15 and this interaction may be essential for the common *Aspergillus fumigatus* colonization in
16 CF patients.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 Traditionally, neutrophils have been traditionally described to be devoid of CFTR
41 expression. However, recent studies indicate that neutrophils express CFTR in
42 lysophagosomes¹⁴⁵⁻¹⁴⁷. These studies demonstrate that CF neutrophils are defective in
43 chlorination of phagocytosed bacteria and further suggest that CFTR as chloride channel is
44 involved in the MPO-hydrogen peroxide-chloride-mediated microbicidal function, relevant
45 for killing of *P. aeruginosa*^{145,146}. These studies using primary human neutrophils were
46 extended by showing that iRNA-mediated knock-down of *CFTR* in neutrophil-like
47 immortalized HL-60 cells impairs microbicidal effector functionalities²¹² and by
48 demonstrating that Zebrafish with reduced *cftr* expression featured impaired respiratory burst
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and neutrophil migration²¹³. The potential role of CFTR in neutrophils has been further
2 supported by studies in mice. Upon pharmacologic or genetic inhibition/deletion of CFTR in
3
4 neutrophils, pro-inflammatory pathways (NF- κ B, MIP-2 and TNF- α) were enhanced and
5
6 reconstitution of wild-type mice with *cfr* F508del neutrophils showed increased pulmonary
7
8 inflammation after LPS challenge²¹⁴. What is currently completely unknown is the
9
10 turnover/survival of neutrophils in the CF airway microenvironment. Recent studies
11
12 challenged the paradigm that neutrophils are short-lived cells and showed, using sophisticated
13
14 *in vivo* neutrophil labelling methodology, that neutrophils live for 5.4 days in healthy
15
16 individuals²¹⁵. Future studies are required to assess the neutrophil turnover / life-span in CF
17
18 airways to evaluate the effects of currently used anti-inflammatory drugs, such as
19
20 corticosteroids and ibuprofen, in CF patients.
21
22
23
24
25
26
27

28 In summary, the neutrophil is quantitatively the predominant cell in the airways of CF
29
30 lung disease and contributes to disease progression through release of oxidants, proteases and
31
32 other proteins. A major challenge for future studies in the field will be the in-depth
33
34 characterization of neutrophil turnover and subset functionality in CF lung disease in order to
35
36 identify specific neutrophil subtypes relevant for disease monitoring and therapeutic targeting.
37
38
39
40

41 ***Macrophages and dendritic cells***

42
43 Alveolar macrophages (M Φ s), together with the epithelium, are part of the lung's innate
44
45 cellular surveillance system. M Φ s efficiently phagocytize bacteria, dead cells and debris and
46
47 M Φ ' activation by external triggers (viruses, bacteria, bacterial products, etc.) leads to a
48
49 cascade of events that contribute to the migration of neutrophils into the alveolar space and,
50
51 eventually, to the activation of dendritic cells and T cells, initiating the adaptive arm of
52
53 immune response.
54
55
56
57

58 The number of alveolar M Φ s in young, non infected CF patients has been reported to
59
60 be elevated compared to non-CF individual controls¹²⁵, suggesting a constitutive/intrinsic and
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

early mononuclear inflammation in CF. The high number of MΦs in CF BAL correlated with an increased concentration of the monocyte chemoattractant chemokine (MCP-1) CCL2^{124,125}. A similar phenotype is observed in the BAL of several CF mouse models^{216,217}. During an inflammatory response, MΦs are differentiated toward distinct subpopulations, which have different functionalities²¹⁸. The so-termed “classically” or “M1” MΦs represent inflammatory cells that produce high amounts of pro-inflammatory cytokines and have accentuated anti-microbial activity. M1 MΦs are generally polarized by exposure to pathogen products (e.g. LPS) and interferon-gamma (INF- γ). The “alternatively” (M2) activated MΦs instead have an immunomodulating function, and promote tissue remodeling and repair after an inflammatory stress response. However, under pathological condition, M2 cells can also mediate chronic inflammation and tissue fibrosis. M2 MΦs are polarized by cytokines that are characterized by a T helper (Th) 2 response, such as IL-4 IL-13 or IL-10. Adequate activation of an inflammatory response and the subsequent resolution requires the balanced and coordinated activity of both MΦs subpopulations. There has been some attempt to study MΦs polarization in CF patients, however, results are inconclusive so far. Circulating CF monocytes²¹⁹ and macrophages isolated from BAL fluid from *P. aeruginosa* infected CF patients²²⁰ exhibit a M2 phenotype compared to controls, while MΦs isolated from CF nasal polyp explants showed a M1 profile²²¹. Studies on murine CF alveolar MΦs suggest that these cells, in absence of any inflammatory triggers, express an M1 polarization profile, and therefore remain in a pro-inflammatory state. Murine CF alveolar MΦs show an exacerbated expression of M1 activation markers when polarized with LPS/INF- γ ; the M2 activation also tends to be elevated in CF MΦs²²². In a subsequent study, it has been reported that, in comparison to healthy controls, the analysis of MΦs isolated from induced sputum of CF patients revealed a pronounced expansion of a unique small CD14⁺ DR⁺ CD68^{dim} population characterized by reduced expression of the scavenger receptors macrophage receptor with collagenous structure (MARCO) and CD206 (mannose receptor). The authors speculate that

1 MΦs with altered plasma membrane receptor profile may lead to impaired clearance of
2 inhaled particles and apoptotic cell, and increased inflammation and damage in CF lungs¹²⁴.
3
4 Thus, MΦs from CF lungs display differences in number and phenotype, which can be the
5 result of exposure to the CF lung environment and/or of cell-intrinsic/autonomous CF MΦs
6 defects.
7
8
9

10
11 Based on these observations of skewed macrophage phenotypes in CF, the questions
12 arises whether these changes are just reflecting inflammation and infection in CF or whether
13 macrophages directly contribute to the pathogenesis of CF lung disease? The creation of
14 stable bone marrow (BM) chimeras, in which WT and CF mice were total body irradiated,
15 transplanted with either WT BM or CF BM and, three months later challenged with LPS,
16 demonstrated that the enhanced secretion of pro-inflammatory cytokines (most of which are
17 abundantly secreted by macrophages) depended on the lack of functional CFTR in immune
18 rather than resident epithelial cells. In contrast, the exuberant migration of neutrophils in the
19 airspace derived from the absence of CFTR in both epithelial cells and immune cells²¹⁷. These
20 data were elegantly corroborated on a myeloid specific *Cftr* *-/-* mouse model generated by the
21 Cre-recombinase LoxP system in which *Cftr* exon 10 was floxed under the control of the
22 myeloid specific promoter lysozyme. After ten days of exposure with *P. aeruginosa* intra-
23 tracheally, the myeloid specific deletion of *Cftr* featured an impaired ability to resolve
24 infection and inflammation with an increased number of BAL cells, increased concentration
25 of pro-inflammatory cytokines, reduced survival, greater weight loss, and more severe clinical
26 and lung pathology scores compared to controls²²³. The contribution of CF MΦs to the *P.*
27 *aeruginosa*-related lung pathology was milder in a CF mouse model (G551D⁻/G551D⁻) in
28 which the tissue specific expression of functional *Cftr* was achieved by gene
29 complementation²²⁴. When viewed in combination, these studies provide experimental
30 evidence supporting the notion that immune cells actively contribute to CF-related lung
31 disease.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The question arises which dysfunctions characterize CF MΦs? In CF pigs²²⁵, a model
2 that is greatly helping to increase our knowledge of disease progression, a bacterial clearance
3 defect establishes from the time of birth, suggesting that non-functional CFTR gives rise to a
4 primary host response defect, despite total cells, numbers of neutrophils and CXCL8 levels
5 did not differ between CF and control pigs. In-depth immunological studies will be essential
6 to dissect the various components of the innate immune system and their potential impairment
7 in CF pigs.
8
9

10
11
12
13
14
15
16
17 Although changes in the CF lung environment, such as decreased secretion of anti-
18 bactericidal molecules by submucosal gland and epithelial cells; abnormal ASL ion
19 composition and pH, may contribute to this defect, there is evidence that absence of
20 functional CFTR leads to impaired bacterial killing in murine²²⁶⁻²²⁹ and human²³⁰ MΦs,
21 suggesting that reduced MΦ bactericidal activity may impair the maintenance of CF lung
22 sterility. Macrophages also play a crucial role in the production of cytokines during the innate
23 immune response. Human^{231,232} and murine^{233,234,222,217} CF MΦs were found to be hyper-
24 responsive when exposed to the bacterial endotoxin LPS, with enhanced signal transduction
25 through the NF-κB and MAPK pathways^{231,234,232}, increased secretion of pro-inflammatory
26 cytokines^{233,217,232} and alteration of LPS-induced metabolic pathways (e.g. PPAR/LXR)²³⁴.
27 Interestingly, secretion of pro-inflammatory cytokines was correlated with the amount of
28 functional CFTR, as MΦs isolated from obligated carriers²³¹ or from mice heterozygous for
29 the *Cftr*-null allele²¹⁷ had a concentration of inflammatory cytokines between non-affected
30 and CF-affected cells. In contrast, murine CF MΦs exposed to *P. aeruginosa* for two hours
31 did not differ in chemokine secretion²⁸. These studies indicate that the CF MΦ's hyper-
32 responsiveness to bacterial products may contribute to the exuberant migration of other
33 immune cells to the lungs and, therefore, to the resulting lung damage.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

59 Based on these studies, it remains to be considered whether MΦs express functional
60 CFTR and whether the observed MΦ phenotypes in CF are cell-intrinsic. The expression of
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

CFTR in non-epithelial tissues has been described²³⁵, however, the impact of non-functional CFTR in non-epithelial cells is becoming better understood with the recent development of a mouse model in which the expression of CFTR can be abolished in a tissue-specific manner. At low levels, the CFTR protein is detectable in both murine MΦs^{227,229} and human MΦs²³⁶ and the CFTR-like Cl⁻ conductance has been recorded in monocytes/MΦs^{230,236,228,229,232}, suggesting that in these cells CFTR functions as a cAMP-dependent chloride channel. In addition, inhibition of functional CFTR in wild-type MΦs led to a phenotype that resembles CF MΦs^{227,230,232}. Thus, CF MΦs express functional CFTR, suggesting that CF MΦs dysfunctions are cell-autonomous rather than a consequence of MΦs exposure to the CF lung surrounding micromilieu.

Given these studies supporting the notion that MΦ express CFTR, it remains to be discussed by which mechanisms non-functional CFTR leads to MΦ' dysfunctions? It has been proposed that CF MΦs fail to kill bacteria due to defective phagolysosome acidification as a result of a Cl⁻-related electrogenic imbalance^{227,228}. However, this finding was challenged by other investigators showing that phagolysosomal acidification in MΦ was not dependent on CFTR channel activity²³⁷. In a more complex scenario, the alteration of the pH in cellular vesicles led to the malfunction of a pH-sensitive enzyme (acid sphingomyelinase) involved in ceramide metabolism. The release of ceramide during *P. aeruginosa* infection in alveolar MΦs favors the formation of ceramide-enriched membrane platforms, which mediates the assembly and activation of the NADPH oxidase²⁸. This complex triggers the production of reactive oxygen species, which, in turn, favor the killing of *P. aeruginosa*. In CF MΦs, ceramide has been shown to accumulate in vesicles, impairing the formation of ceramide-reach membrane platforms and activation of the NADPH complex. However, the role of CFTR in controlling vesicle pH remains controversially discussed^{238,239}; discrepancies that are likely due to differences in experimental settings. An additional observation is that the phagosome Cl⁻ concentration can modulate the behavior of intracellular bacteria by altering

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

bacterial protein activity or host factors. For instance, the CFTR-mediated Cl⁻ flux in MΦs contributes to the *L. monocytogenes* phagosomal escape to the host cytosol by favoring its hemolytic activity²²⁹. In addition, the defective CFTR-mediated Cl⁻ flux in CF MΦs was found to impair autophagy and autophagosome formation during *B. cepacia* infection. CF mouse MΦs infected with *B. cepacia* downregulated the expression of autophagy-related genes compared to WT cells, impairing the autophagosomes-lysosomes fusion and thus reducing bacterial clearance. Prolonged *B. cepacia* survival in CF MΦs has been associated with increased secretion of the pro-inflammatory cytokine IL-1β²²⁶. CF MΦs are also characterized by defective endosomes to late-endosomes/lysosomes maturation during LPS challenge. This defect was shown to lead to dysregulated TLR4 trafficking from the plasma membrane to the lysosomes, where the activated TLR4 is degraded. As a result, CF MΦs were shown to feature a more robust TLR4 signaling with an increased secretion of pro-inflammatory cytokines compared to WT cells²³². Studies analyzing human monocytes in CF patients and control subjects found that the receptor *Triggering receptor expressed on myeloid cells 1* (TREM1) was downregulated on circulating CF monocytes and that this was associated with circulating PAMPs and an unresponsiveness / tolerance state toward LPS in CF^{240,241}. This finding is in contrast to studies using murine CFTR^{-/-} or human CF patient macrophages. The underlying reasons are not fully understood, but based on the notion that monocytes upregulate a large array of genes upon entering the airways and differentiation to alveolar macrophages²⁴², it is conceivable that this differentiation process modulates the CFTR-related responsiveness towards PAMPs and DAMPs. Nevertheless, these discrepant observations necessitate future studies in the field of monocytes/macrophages in CF, utilizing both murine and human experimental systems.

Macrophages represent the main scavengers of apoptotic neutrophils, a process termed efferocytosis²⁴³. Efferocytosis is essential in compartments where large numbers of neutrophils accumulate and undergo ageing and apoptosis, such as the CF airways where

1
2 large numbers of particularly neutrophils undergo several forms of apoptosis and cell
3 death²⁴⁴. Successful efferocytosis prevents secondary necrosis and pro-inflammatory cascades
4 and thereby acts anti-inflammatory. Notably, previous studies found that clearance of
5 apoptotic cells is impaired in the CF microenvironment due to elastase-mediated cleavage of
6 phosphatidylserine receptors or other CFTR-related mechanisms in epithelial cells²⁴⁵⁻²⁴⁷.
7
8 These findings underpin the complexity of the initiation, maintenance, resolution and
9
10 perpetuation of neutrophilic inflammation in CF. **Figure 3 summarizes the complex role and**
11
12 **paracrine interaction partners of macrophages in CF lung disease.**
13
14
15
16
17
18

19 CF-DCs challenged with *P. aeruginosa* were found to exhibit an abnormal expression
20
21 of genes involved in the maintenance of membrane structure and lipid-metabolism; in
22
23 addition, CF DCs displayed a delay in the early phase of differentiation^{248,249}. On the other
24
25 hand, neutrophil elastase in CF airway fluids was found to inhibit DC maturation and
26
27 functionality by shedding CD86 and impairing antigen presentation capabilities²⁵⁰. In
28
29 combination, these data suggests that in CF, the cross-talk between the innate and the adaptive
30
31 immune response, orchestrated by DCs, may also be compromised, caused by CFTR-
32
33 dependent and CFTR-independent proteolytic mechanisms. More studies are needed to
34
35 dissect the role of this arm of the immune system in the development of CF lung disease.
36
37
38
39
40

41 Taken together, these observations suggest that CF MΦs display several cell-
42
43 autonomous/intrinsic dysfunctionalities that alter their ability to properly control their
44
45 response to inflammatory triggers and to kill bacteria in the context of CF lung disease. In the
46
47 early stages of CF lung disease, the inappropriate MΦ behavior may contribute to conditions
48
49 that favor bacterial lung adaptation, harmful chronic infection, and lung damage.
50
51
52
53
54
55
56

57 **v. Th17 cells link innate and adaptive immunity**

58
59
60
61
62
63
64
65

1
2 While neutrophils are the dominant cell population in the broncho-alveolar compartment
3 (bronchial > alveolar), recent studies indicate that T cells accumulate within the subepithelial
4 bronchial tissue but are almost devoid of the bronchial space²⁵¹, supporting the notion that the
5 pulmonary immune system is compartmentalized and the role of T cells has probably been
6 under-appreciated in CF lung disease due to their paucity in sputum or BALF²⁵²⁻²⁵⁴.

7
8
9
10
11
12 In recent years, there have been significant advances in our understanding of T cell
13 subsets beyond the canonical Th1/Th2 paradigm. It is now widely accepted that a normal
14 immune system harbours a regulatory T cell population specialized for immune suppression,
15 as well as a Th17 cell subset that mediates inflammatory processes and autoimmunity²⁵⁵.
16 Th17 cells are CD4⁺ T cells that produce IL-17-like cytokines named IL-17-A/F, besides IL-
17 22 and other effector cytokines, and regulate both granulopoiesis and recruitment of
18 neutrophils into sites of inflammation, thereby linking innate and adoptive immunity²⁵⁶. IL-17
19 signals through the IL-17 receptor (IL-17R), a type I transmembrane protein which is
20 ubiquitously expressed in tissues. IL-17 can stimulate a number of different cell types
21 including macrophages, dendritic cells, endothelial cells or fibroblasts to release effector
22 molecules leading to pathology²⁵⁷. Th17 cells are activated by IL-23, mainly derived from
23 dendritic cells and macrophages, as well as by IL-6 and TGF- β ²⁵⁸.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
There is a rapidly growing body of evidence that IL-17-related pathways are involved
in the immunopathogenesis of a broad spectrum of inflammatory human disease conditions,
including multiple sclerosis, rheumatic diseases, inflammatory bowel disease, asthma, and
atopic dermatitis²⁵⁹. In the lungs, IL-17 has been shown to be crucial for maintaining control
of host defence against extracellular pathogens. It was demonstrated that IL-17, and its
driving factor IL-23, are important for maintaining mucosal host defence against *Klebsiella*
pneumoniae infection in human bronchial epithelial cells. In mice, IL-17 and IL-23 are
involved in host responses to infection by gram-negative bacteria, in particular *Klebsiella*, *P.*
aeruginosa, *Escherichia coli*, *Salmonella* and *Bordetella species*^{256,260,261}. The potential role

of IL-17-related pathways in CF lung disease is now greatly supported by a considerable number of recent studies^{162,262,263}. Of particular interest for CF lung disease may be the observations that IL-23 and IL-17 mediate inflammatory response to mucoid *P. aeruginosa* infection and are critical for neutrophil inflammation²⁶⁴. The IL-23-driven recruitment of neutrophil inflammation is, however, not uniquely dependent on IL-17: newer studies suggest that in addition to IL-17 production by $\gamma\delta$ T cells after IL-23 stimulation, neutrophil recruitment is promoted by IL-23 independently of IL-17 in an early inflammation phase²⁶⁵. In human studies, IL-17 and IL-23 were markedly elevated in BAL fluid or sputum of CF patients with chronic *P. aeruginosa* colonization undergoing pulmonary exacerbation as well as in explanted CF lungs^{162,266,267}. A more recent study likewise found substantially increased levels of IL-17 protein and mRNA, and IL-23 in the sputum of stable CF patients²⁶⁸. This observation was especially pronounced in patients chronically infected with *P. aeruginosa*, further pointing to an important role of IL-17 in the neutrophil inflammation of CF lung disease.

Though Th17 cells are regarded as the major producer of IL-17, other cellular sources have been associated with production of IL-17 depending on the underlying pathology, especially $\gamma\delta$ T cells, natural killer T cells and CD8⁺ T cells²⁵⁶. Beyond these cell types, IL-17 protein was detected also in eosinophils, mastcells, neutrophils and human blood monocytes^{266,267}. In CF, the complexity of IL-17-producing cells has recently been nicely demonstrated by Tan and colleagues analysing endobronchial biopsies. They showed that IL-17 cell counts were significantly increased in lung tissue of young children with established CF compared to healthy controls²⁶⁹. Whereas Th17 cells were the predominant IL-17-producing cell type in the airway walls of newly diagnosed as well as established CF and non-CF bronchiectasis, other important sources of IL-17 were NKT cells (in end stage lung disease) and γ δ T cells. IL-17-producing cell counts depended on severity, as young children showed intermediate counts compared to end stage lung disease. Similar observation

1 was made for IL-17 levels in BAL. However, not only lymphocytes seems to contribute to IL-
2 17-related immunity CF. Immunohistochemistry staining of explanted CF lungs suggested that
3 IL-17 is increased in lower airways compared to non-CF lung tissue, and that IL-17
4 production localizes to neutrophils^{266,267}. The observation that elevated numbers of IL-17-
5 producing cells are already found in early lung disease in very young CF patients and the
6 correlation of disease severity and *P. aeruginosa* colonisation to IL-17⁺ cells and IL-17
7 protein levels in BAL fluid render IL-17 and associated cytokines potentially interesting
8 biomarkers for monitoring CF lung inflammation. In addition to their potential value as
9 biomarkers, IL-17-related cytokines such as anti-IL-17 or anti-IL-23 antibodies may be
10 therapeutic targets to modify pulmonary inflammation in CF.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 However, great therapeutic caution needs to be applied in an environment of enhanced
25 infection susceptibility, as it is the CF lung. Suppressing of one particular inflammatory
26 pathway may result in uncontrolled bacterial growth and severe pulmonary exacerbation. For
27 these reasons, a deep understanding of the IL-17-related pathways in the context of CF lung
28 disease is critical to assess the potential implications of an anti-IL-17 therapy, or interventions
29 targeting its cellular source. Beyond Th17, previous studies provided evidence that
30 lymphocytes from CF patients exhibit a cytokine dysregulation with an intrinsic Th2
31 bias^{270,271} and increased Nuclear Factor of Activated T Cell (NFAT) translocation due to the
32 cellular CFTR defect, a topic related to adaptive immunity that is reviewed in greater detail in
33 a recent review³⁴.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 vi. Innate immunity in CF – any relevance?

52 Innate immunity in CF is a growing field of interest in both basic and translational research.
53 Within the previous years, it turned out that the interplay between cellular and soluble, CFTR-
54 dependent and –independent and pathogen-associated and sterile pathomechanisms are of
55 higher complexity than previously expected. While the link between the basic CF defect and
56
57
58
59
60
61
62
63
64
65

innate immune inflammation is increasingly appreciated²⁷², key questions on the survival, subsets and functionalities of phagocytes in CF airways remain controversial.

Single nucleotide polymorphisms (SNPs) in genes involved in innate immunity, such as mannose binding lectin 2 (MBL2)²⁷³⁻²⁷⁸, Transforming growth factor β (TGF- β)²⁷⁹, CD14²⁸⁰, Interferon-related developmental regulator 1 (IFRD1)²⁸¹ and others, as well as recent genome-wide association studies add another layer of complexity^{279,282,283}. Considering the manifold components and mechanisms of innate immunity in CF lung disease, the question remains which diagnostic or therapeutic relevance remains for the clinician. Diagnostically, several immune proteins, proteases or proteolytically-generated peptides, such as CXCL8/IL-8, IL-6, TNF- α , YKL-40, TGF- β , PGP, HMGB1, AAT:CD16, elastase or MMP-9 have been proposed as biomarkers for CF lung disease, but their clinical usefulness requires further cross-sectional multi-center and longitudinal studies to understand their kinetics, treatment responses and comparing their reliability, validity and cost-effectiveness. Therapeutic consequences seem to be farer on the horizon and have to be implemented with great caution^{2,284,285,286}, since interfering with innate immune recruitment or effector mechanisms harbours the risk of disabling innate host defense mechanisms and favoring bacterial and fungal infections. Therefore, future studies dissecting the kinetics and dynamics of the innate immune system in cells, mice, ferrets, pigs and humans will be essential to identify specific cell populations or released proteins that are worth targeting in a time- and inflammation-specific manner in CF lung disease.

ACKNOWLEDGEMENTS

Supported by the NIH (HL102371-01A1 to AG), CF Foundation (GAGGAR07A0 to AG),
DFG (MA 2081/3-3 and MA 2081/4-1 to MAM; Emmy Noether Programme HA 5274/3-1 to
D.H.) and BMBF (DZL to MAM).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

TABLES

TABLE 1

Innate immune cell	Functional role	Impairment in CF lung disease
Neutrophils	<ul style="list-style-type: none"> • Anti-bacterial and-fungal host defense • Cytokine / chemokine release 	<ul style="list-style-type: none"> • Impaired chlorination / intracellular killing of phagocytosed bacteria • Delayed apoptosis • Impaired phagocytosis* • Proteolytic and oxidative tissue damage • Cleavage of leukocyte surface receptors • DNA release (necrosis / NETosis) • Increased elastase release • Enhanced chemotaxis
Macrophages / Monocytes	<ul style="list-style-type: none"> • Anti-bacterial and-fungal host defense • Removal of apoptotic cells (efferocytosis) • Antigen-presentation • Cytokine/ chemokine release • Immune regulation 	<ul style="list-style-type: none"> • Increased secretion of pro-inflammatory cytokines • Impaired intracellular killing of bacteria* • Defective phagolysosomal acidification* • Disturbed ceramide metabolism • Dysregulated TLR4 trafficking • Downregulated autophagy

		<ul style="list-style-type: none"> • <i>Macrophages</i>: Hyper-responsiveness towards LPS • <i>Monocytes</i>: Downregulation of TREM / Hyporesponsiveness to LPS • M1 / M2 dysregulation* • Reduced expression of scavenger receptors • Cleavage of phosphatidylserine receptors / impaired efferocytosis
T cells	<ul style="list-style-type: none"> • Anti-bacterial, -fungal and -viral host defense • Antibody production • Neutrophil recruitment (Th17) • Allergic responses (ABPA, Th2) • Immune regulation (Tregs) 	<ul style="list-style-type: none"> • CFTR-mediated Th2 shift • <i>Pseudomonas aeruginosa</i>-mediated Th2 shift • Th17 activation • <i>Pseudomonas aeruginosa</i>-mediated impairment of T cell proliferation

* controversial studies

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **FIGURE LEGENDS**
3

4 **Figure 1. Mechanisms initiating neutrophil influx into the CF Lung**
5

6
7 Panel A represents the healthy airway; Panel B represents the CF airway. Airway surface
8
9 liquid (ASL) is reduced in the CF airway, leading to decreased mucociliary transport and
10
11 bacterial colonization. In response to bacteria (blue ovals), epithelial cells in CF patients
12
13 release CXCL8, resulting in neutrophil influx. Degranulation of activated neutrophils
14
15 releases MMP-9 and PE (red circles) as well as LTA4H (green triangles). In healthy
16
17 individuals, LTA4H is able to degrade PGP generated by MMP-9 and PE-mediated cleavage
18
19 of collagen, while unopposed proteolytic cascades in CF patients lead to PGP generation,
20
21 triggering neutrophil influx and thereby perpetuating inflammation.
22
23
24
25
26
27
28

29 **Figure 2. Neutrophil flexibility in CF**
30

31
32 When neutrophils in CF airways are exposed to PAMPs and/or DAMPs, distinct effector
33
34 functions are activated depending on the duration and the severity of the PAMP/DAMP
35
36 contact. Neutrophils rapidly phagocytose bacteria. As CFTR is localized in the
37
38 phagolysosome, CF neutrophils feature an intrinsic phagocytotic dysregulation depending on
39
40 phagolysosomal chlorination. Extracellular pathogens and tissue structures are attacked by
41
42 granule release. CF neutrophils feature an increased release of primary granules (1 G), while
43
44 characteristics of secondary (2 G) and tertiary (3 G) granules in CF versus healthy neutrophils
45
46 have not been studied so far. After prolonged stimulation, NETs are generated to entangle
47
48 extracellular bacteria and fungi. NET formation capacity does not differ between CF and
49
50 control peripheral blood neutrophils.
51
52
53
54
55
56
57

58 **Figure 3. Macrophage flexibility in CF**
59
60
61
62
63
64
65

1 The figure illustrates the complex involvement of macrophages in host-pathogen and cell-cell
2 interactions in CF lung disease. CF macrophages are hyper-responsive when exposed to
3
4 bacterial (such as *P. aeruginosa* derived) PAMPs, with enhanced signal transduction and
5
6 increased secretion of pro-inflammatory cytokines. Through secretion of cytokines, alveolar
7
8 macrophages communicate with neutrophils, lymphocytes, dendritic cells and epithelial cells,
9
10 thereby orchestrating the outcome of the pulmonary immune response in CF. In addition, CF
11
12 macrophages have been described to show defective intracellular bacterial killing
13
14 (controversial finding) and apoptotic cell removal (efferocytosis) activities. In summary, these
15
16 dysfunctions may led to altered paracrine signaling within the CF lung environment.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Pillarisetti N, Williamson E, Linnane B, et al. Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis. *Am J Respir Crit Care Med.* Jul 1 2011;184(1):75-81.
2. Ratjen F. What's new in CF airway inflammation: an update. *Paediatr Respir Rev.* 2006;7 Suppl 1:S70-72.
3. Ratjen F. Diagnosing and managing infection in CF. *Paediatr Respir Rev.* 2006;7 Suppl 1:S151-153.
4. Sagel SD, Dowell EB, Accurso FJ. Bacterial colonization and infection in the CF lung. *Methods Mol Med.* 2002;70:433-446.
5. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest.* Mar 2002;109(5):571-577.
6. Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: Lessons from mouse models. *J Aerosol Med Pulm D.* Mar 2008;21(1):13-24.
7. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. *J Clin Invest.* Feb 1999;103(3):303-307.
8. Koller B, Bals R, Roos D, Korting HC, Griese M, Hartl D. Innate immune receptors on neutrophils and their role in chronic lung disease. *Eur J Clin Invest.* Jul 2009;39(7):535-547.
9. Greene CM, Carroll TP, Smith SGJ, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol.* Feb 1 2005;174(3):1638-1646.
10. Thelin WR, Kesimer M, Tarran R, et al. The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A. *J Biol Chem.* Dec 16 2005;280(50):41512-41520.
11. Kreda SM, Mall M, Mengos A, et al. Characterization of wild-type and Delta F508 cystic fibrosis transmembrane regulator in human respiratory epithelia. *Mol Biol Cell.* May 2005;16(5):2154-2167.
12. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside Triphosphates Are Required to Open the Cftr Chloride Channel. *Cell.* Nov 15 1991;67(4):775-784.
13. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration That Cftr Is a Chloride Channel by Alteration of Its Anion Selectivity. *Science.* Jul 12 1991;253(5016):202-205.
14. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. *Science.* Oct 24 2008;322(5901):590-594.
15. Stutts MJ, Canessa CM, Olsen JC, et al. Cftr as a Camp-Dependent Regulator of Sodium-Channels. *Science.* Aug 11 1995;269(5225):847-850.
16. Mall MA. Role of the amiloride-sensitive epithelial Na⁺ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. *Exp Physiol.* Feb 2009;94(2):171-174.
17. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. *Cell.* Dec 23 1998;95(7):1005-1015.

- 1 **18.** Tarran R, Button B, Boucher RC. Regulation of normal and cystic fibrosis airway
2 surface liquid volume by phasic shear stress. *Annu Rev Physiol.* 2006;68:543-561.
- 3 **19.** Zhou Z, Duerr J, Johannesson B, et al. The ENaC-overexpressing mouse as a model
4 of cystic fibrosis lung disease. *J Cyst Fibros.* Jun 2011;10 Suppl 2:S172-182.
- 5 **20.** Wilke M, Buijs-Offerman RM, Aarbiou J, et al. Mouse models of cystic fibrosis:
6 phenotypic analysis and research applications. *J Cyst Fibros.* Jun 2011;10 Suppl
7 2:S152-171.
- 8 **21.** Davidson DJ, Dorin JR. The CF mouse: an important tool for studying cystic
9 fibrosis. *Expert Rev Mol Med.* Mar 12 2001;2001:1-27.
- 10 **22.** Davidson DJ, Rolfe M. Mouse models of cystic fibrosis. *Trends Genet.* Oct
11 2001;17(10):S29-37.
- 12 **23.** Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for
13 cystic fibrosis. *Physiol Rev.* Jan 1999;79(1 Suppl):S193-214.
- 14 **24.** Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway
15 epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice. *Nat*
16 *Med.* May 2004;10(5):487-493.
- 17 **25.** Mall MA, Harkema JR, Trojanek JB, et al. Development of chronic bronchitis and
18 emphysema in beta-epithelial Na⁺ channel-overexpressing mice. *Am J Respir Crit*
19 *Care Med.* Apr 1 2008;177(7):730-742.
- 20 **26.** Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy
21 reduces morbidity and mortality of lung disease in betaENaC-overexpressing
22 mice. *Am J Respir Crit Care Med.* Dec 15 2008;178(12):1245-1256.
- 23 **27.** Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates
24 inflammation, cell death and infection susceptibility in cystic fibrosis. *Nat Med.*
25 Apr 2008;14(4):382-391.
- 26 **28.** Zhang Y, Li X, Grassme H, Doring G, Gulbins E. Alterations in Ceramide
27 Concentration and pH Determine the Release of Reactive Oxygen Species by Cftr-
28 Deficient Macrophages on Infection. *J Immunol.* May 1 2010;184(9):5104-5111.
- 29 **29.** Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. *J*
30 *Cyst Fibros.* May 2010;9(3):217-227.
- 31 **30.** Campana S, Taccetti G, Ravenni N, et al. Molecular epidemiology of *Pseudomonas*
32 *aeruginosa*, *Burkholderia cepacia* complex and methicillin-resistant
33 *Staphylococcus aureus* in a cystic fibrosis center. *J Cyst Fibros.* Aug
34 2004;3(3):159-163.
- 35 **31.** Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic
36 fibrosis: a European consensus. *J Cyst Fibros.* Jun 2004;3(2):67-91.
- 37 **32.** Chmiel JF, Berger M, Konstan MW. The role of inflammation in the
38 pathophysiology of CF lung disease. *Clin Rev Allergy Immunol.* Aug 2002;23(1):5-
39 27.
- 40 **33.** Davis PB, Drumm M, Konstan MW. Cystic fibrosis. *Am J Respir Crit Care Med.* Nov
41 1996;154(5):1229-1256.
- 42 **34.** Ratner D, Mueller C. Immune responses in Cystic Fibrosis; are they intrinsically
43 defective? *Am J Resp Cell Mol.* Mar 8 2012.
- 44 **35.** Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with
45 cystic fibrosis and the G551D mutation. *N Engl J Med.* Nov 3 2011;365(18):1663-
46 1672.
- 47 **36.** Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic
48 fibrosis and the G551D-CFTR mutation. *N Engl J Med.* Nov 18
49 2010;363(21):1991-2003.
- 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 37. Hirtz S, Gonska T, Seydewitz HH, et al. CFTR Cl⁻ channel function in native human
2 colon correlates with the genotype and phenotype in cystic fibrosis.
3 *Gastroenterology*. Oct 2004;127(4):1085-1095.
- 4 38. Roth EK, Hirtz S, Duerr J, et al. The K⁺ channel opener 1-EBIO potentiates
5 residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients.
6 *Plos One*. 2011;6(8):e24445.
- 7 39. Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in
8 cystic fibrosis. *Curr Opin Pulm Med*. Nov 2010;16(6):598-603.
- 9 40. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG.
10 Sputum *Candida albicans* presages FEV(1) decline and hospital-treated
11 exacerbations in cystic fibrosis. *Chest*. Nov 2010;138(5):1186-1195.
- 12 41. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical
13 significance of *Scedosporium apiospermum* in patients with cystic fibrosis. *Eur J*
14 *Clin Microbiol Infect Dis*. Jan 2000;19(1):53-56.
- 15 42. Bendiak GN, Ratjen F. The approach to *Pseudomonas aeruginosa* in cystic
16 fibrosis. *Semin Respir Crit Care Med*. Oct 2009;30(5):587-595.
- 17 43. Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA link. *Med*
18 *Mycol*. 2009;47:S183-S191.
- 19 44. Thursfield RM, Holden K, Bush A, Adams A, Nicholson AG. What Is the
20 Significance of *Aspergillus Fumigatus* in Bal in Children with Cystic Fibrosis.
21 *Pediatr Pulmonol*. 2011:304-304.
- 22 45. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in *Pseudomonas*
23 *aeruginosa*-infected patients with cystic fibrosis. *J.Allergy Clin.Immunol*.
24 2006;117(1):204-211.
- 25 46. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity:
26 update on Toll-like receptors. *Nat Immunol*. May 2010;11(5):373-384.
- 27 47. Kawai T, Akira S. Toll-like Receptors and Their Crosstalk with Other Innate
28 Receptors in Infection and Immunity. *Immunity*. May 27 2011;34(5):637-650.
- 29 48. Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. *Cell*. Mar
30 19 2010;140(6):805-820.
- 31 49. Armstrong L, Medford AR, Uppington KM, et al. Expression of functional toll-like
32 receptor-2 and -4 on alveolar epithelial cells. *Am J Resp Cell Mol*. Aug
33 2004;31(2):241-245.
- 34 50. Droemann D, Goldmann T, Branscheid D, et al. Toll-like receptor 2 is expressed
35 by alveolar epithelial cells type II and macrophages in the human lung. *Histochem*
36 *Cell Biol*. Feb 2003;119(2):103-108.
- 37 51. Greene CM, Branagan P, McElvaney NG. Toll-like receptors as therapeutic targets
38 in cystic fibrosis. *Expert Opin Ther Targets*. Dec 2008;12(12):1481-1495.
- 39 52. Muir A, Soong G, Sokol S, et al. Toll-like receptors in normal and cystic fibrosis
40 airway epithelial cells. *Am J Resp Cell Mol*. Jun 2004;30(6):777-783.
- 41 53. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from
42 the ER to CpG DNA in the lysosome. *Nat Immunol*. Feb 2004;5(2):190-198.
- 43 54. Platz J, Beisswenger C, Dalpke A, et al. Microbial DNA induces a host defense
44 reaction of human respiratory epithelial cells. *J Immunol*. Jul 15
45 2004;173(2):1219-1223.
- 46 55. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic
47 fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol*. Feb 1
48 2005;174(3):1638-1646.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
56. Adamo R, Sokol S, Soong G, Gomez MI, Prince A. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. *Am J Respir Cell Mol Biol.* May 2004;30(5):627-634.
57. Monick MM, Yarovinsky TO, Powers LS, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. *J Biol Chem.* Dec 26 2003;278(52):53035-53044.
58. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. *J Clin Invest.* May 2004;113(10):1482-1489.
59. Muir A, Soong G, Sokol S, et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. *Am J Respir Cell Mol Biol.* Jun 2004;30(6):777-783.
60. Hauber HP, Tulic MK, Tsicopoulos A, et al. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. *Can Respir J.* Jan-Feb 2005;12(1):13-18.
61. John G, Yildirim AO, Rubin BK, Gruenert DC, Henke MO. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. *Am J Respir Cell Mol Biol.* Apr 2010;42(4):424-431.
62. John G, Chillappagari S, Rubin BK, Gruenert DC, Henke MO. Reduced surface toll-like receptor-4 expression and absent interferon-gamma-inducible protein-10 induction in cystic fibrosis airway cells. *Exp Lung Res.* Aug 2011;37(6):319-326.
63. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. *Nat Med.* 2012;18(4):509-519.
64. Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. *Infect Immun.* Nov 2005;73(11):7151-7160.
65. de CVGM, Le Goffic R, Balloy V, Plotkowski MC, Chignard M, Si-Tahar M. TLR 5, but neither TLR2 nor TLR4, is involved in lung epithelial cell response to Burkholderia cenocepacia. *FEMS Immunol Med Microbiol.* Oct 2008;54(1):37-44.
66. Blohmke CJ, Victor RE, Hirschfeld AF, et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. *J Immunol.* Jun 1 2008;180(11):7764-7773.
67. Blohmke CJ, Park J, Hirschfeld AF, et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. *J Immunol.* Dec 15 2010;185(12):7731-7738.
68. Roussel L, Martel G, Berube J, Rousseau S. P. aeruginosa drives CXCL8 synthesis via redundant toll-like receptors and NADPH oxidase in CFTRF508 airway epithelial cells. *J Cyst Fibros.* Mar 2011;10(2):107-113.
69. Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG. Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. *Respir Care.* Aug 2008;53(8):1035-1041.
70. Beisswenger C, Hess C, Bals R. Aspergillus fumigatus conidia induce interferon-beta signalling in respiratory epithelial cells. *Eur Respir J.* Feb 2012;39(2):411-418.
71. Da Silva CA, Hartl D, Liu W, Lee CG, Elias JA. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. *J Immunol.* Sep 15 2008;181(6):4279-4286.
72. Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. *J Biol Chem.* Sep 21 2001;276(38):35494-35499.

- 1 **73.** Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. *FEBS Lett.* Jun 5 2003;544(1-3):129-132.
- 2
- 3 **74.** Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. *J Immunol.* Sep 15 2005;175(6):4009-4016.
- 4
- 5
- 6 **75.** Bergin DA, Greene CM, Sterchi EE, et al. Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. *J Biol Chem.* Nov 14 2008;283(46):31736-31744.
- 7
- 8 **76.** Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. *J Biol Chem.* Mar 4 2011;286(9):7692-7704.
- 9
- 10 **77.** Chotirmall SH, Greene CM, Oglesby IK, et al. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. *Am J Respir Crit Care Med.* Jul 1 2010;182(1):62-72.
- 11
- 12 **78.** Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. *J Biol Chem.* Sep 13 2002;277(37):33648-33653.
- 13
- 14 **79.** Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. *Infect Immun.* Jun 2004;72(6):3684-3687.
- 15
- 16 **80.** Taggart CC, Cryan SA, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. *J Exp Med.* Dec 19 2005;202(12):1659-1668.
- 17
- 18 **81.** Oglesby IK, Bray IM, Chotirmall SH, et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. *J Immunol.* Feb 15 2010;184(4):1702-1709.
- 19
- 20 **82.** Gerard C, Rollins BJ. Chemokines and disease. *Nat.Immunol.* 2001;2(2):108-115.
- 21
- 22 **83.** Moser B, Loetscher P. Lymphocyte traffic control by chemokines. *Nat Immunol.* Feb 2001;2(2):123-128.
- 23
- 24 **84.** Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. *Curr.Opin.Pulm Med.* 2003;9(2):104-110.
- 25
- 26 **85.** Zemans RL, Briones N, Campbell M, et al. Neutrophil transmigration triggers repair of the lung epithelium via beta-catenin signaling. *P Natl Acad Sci USA.* Sep 20 2011;108(38):15990-15995.
- 27
- 28 **86.** Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. *Am J Resp Cell Mol.* May 2009;40(5):519-535.
- 29
- 30 **87.** Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. *Thorax.* Jan 2009;64(1):81-88.
- 31
- 32 **88.** Russell KJ, McRedmond J, Mukherji N, et al. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. *Am J Respir Crit Care Med.* Mar 1998;157(3 Pt 1):756-761.
- 33
- 34 **89.** Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. *Pediatr Pulmonol.* Aug 2007;42(8):729-735.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
90. Tabary O, Corvol H, Boncoeur E, et al. Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. *Am J Physiol Lung Cell Mol Physiol*. Mar 2006;290(3):L588-596.
91. Owen C. Chemokine receptors in airway disease: which receptors to target? *Pulm Pharmacol Ther*. 2001;14(3):193-202.
92. Yang D, de la Rosa G, Tewary P, Oppenheim JJ. Alarmins link neutrophils and dendritic cells. *Trends Immunol*. Nov 2009;30(11):531-537.
93. Yang D, Oppenheim JJ. Alarmins and antimicrobial immunity. *Medical mycology : official publication of the International Society for Human and Animal Mycology*. 2009;47 Suppl 1:S146-153.
94. Sagel SD, Accurso FJ. Monitoring inflammation in CF. Cytokines. *Clin Rev Allergy Immunol*. Aug 2002;23(1):41-57.
95. Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. *Clin Rev Allergy Immunol*. Apr 2008;34(2):146-162.
96. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. *Chest*. Feb 2008;133(2):489-495.
97. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. *Lab Invest*. Mar 1987;56(3):234-248.
98. Yang M, Kumar RK, Hansbro PM, Foster PS. Emerging roles of pulmonary macrophages in driving the development of severe asthma. *J Leukoc Biol*. Jan 31 2012.
99. Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. *Pediatr Pulmonol*. Jan 1996;21(1):11-19.
100. Osika E, Cavaillon JM, Chadelat K, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. *Eur Respir J*. Aug 1999;14(2):339-346.
101. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. *Arch Dis Child*. Aug 1997;77(2):124-130.
102. Colombo C, Faelli N, Tirelli AS, et al. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. *Int J Immunopathol Pharmacol*. Apr-Jun 2011;24(2):423-432.
103. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood*. Apr 7 2011;117(14):3720-3732.
104. Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. *Pediatr Pulmonol*. Jul 1994;18(1):21-27.
105. Greally P, Hussain MJ, Vergani D, Price JF. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. *Arch Dis Child*. Jun 1993;68(6):785-787.
106. Wilmott RW, Kassab JT, Kilian PL, Benjamin WR, Douglas SD, Wood RE. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. *Am Rev Respir Dis*. Aug 1990;142(2):365-368.
107. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory Cytokines in Cystic-Fibrosis Lungs. *Am J Respir Crit Care Med*. Dec 1995;152(6):2111-2118.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
108. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of *P. aeruginosa* in young children with cystic fibrosis. *Eur Respir J*. Feb 2009;33(2):305-311.
 109. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. *Am J Respir Cell Mol Biol*. Sep 1995;13(3):257-261.
 110. Muhlebach MS, Reed W, Noah TL. Quantitative cytokine gene expression in CF airway. *Pediatr Pulmonol*. May 2004;37(5):393-399.
 111. Buff SM, Yu H, McCall JN, et al. IL-10 delivery by AAV5 vector attenuates inflammation in mice with *Pseudomonas pneumonia*. *Gene Ther*. May 2010;17(5):567-576.
 112. Sagel SD. Noninvasive biomarkers of airway inflammation in cystic fibrosis. *Curr Opin Pulm Med*. Nov 2003;9(6):516-521.
 113. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *Jama*. May 17 2006;295(19):2275-2285.
 114. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med*. Feb 9 2006;354(6):610-621.
 115. Kunkel SL, Strieter RM, Chensue SW, et al. Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines. *Prog Clin Biol Res*. 1990;349:433-444.
 116. Winkler M. Role of cytokines and other inflammatory mediators. *BJOG*. Apr 2003;110 Suppl 20:118-123.
 117. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nat Med*. Dec 2007;13(12):1423-1430.
 118. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. *Am J Respir Crit Care Med*. Apr 15 2007;175(8):822-828.
 119. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. *Am J Respir Crit Care Med*. Oct 15 2001;164(8):1425-1431.
 120. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. *Pediatr Res*. Aug 1993;34(2):159-161.
 121. Karpati F, Hjelte FL, Wretling B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. *Scand J Infect Dis*. 2000;32(1):75-79.
 122. Schmitt-Grohe S, Naujoks C, Bargon J, et al. Interleukin-8 in whole blood and clinical status in cystic fibrosis. *Cytokine*. Jan 7 2005;29(1):18-23.
 123. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. *Chest*. Sep 2004;126(3):926-934.
 124. Rao S, Wright AK, Montiero W, Ziegler-Heitbrock L, Grigg J. Monocyte chemoattractant chemokines in cystic fibrosis. *J Cyst Fibros*. Mar 2009;8(2):97-103.
 125. Brennan S, Sly PD, Gangell CL, et al. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. *European Respiratory Journal*. Sep 2009;34(3):655-661.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
126. Estell K, Braunstein G, Tucker T, Varga K, Collawn JF, Schwiebert LM. Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ-interacting motif. *Mol Cell Biol.* Jan 2003;23(2):594-606.
 127. Schwiebert LM, Estell K, Propst SM. Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. *The American journal of physiology.* Mar 1999;276(3 Pt 1):C700-710.
 128. Hafen GM, Hartl D, Regamey N, Casaulta C, Latzin P. Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patients. *Expert Rev Mol Diagn.* Mar 2009;9(2):157-164.
 129. Hartl D, Buckland KF, Hogaboam CM. Chemokines in allergic aspergillosis--from animal models to human lung diseases. *Inflamm.Allergy Drug Targets.* 2006;5(4):219-228.
 130. Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. *Am J Respir Crit Care Med.* Jun 15 2006;173(12):1370-1376.
 131. Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA. Novel biomarkers in asthma: chemokines and chitinase-like proteins. *Curr Opin Allergy Clin Immunol.* Feb 2009;9(1):60-66.
 132. Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH, Casaulta C. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. *Eur.Respir.J.* 2008;31(1):36-42.
 133. Djekic UV, Gaggar A, Weathington NM. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. *Pharmacol Ther.* Feb 2009;121(2):132-146.
 134. Rowe SM, Jackson PL, Liu G, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. *Am J Respir Crit Care Med.* Oct 15 2008;178(8):822-831.
 135. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. *Nat Med.* Mar 2006;12(3):317-323.
 136. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. *J Immunol.* Apr 15 2008;180(8):5662-5669.
 137. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. *Science.* Oct 1 2010;330(6000):90-94.
 138. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. *Immunol Rev.* Dec 2007;220:35-46.
 139. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. *Science.* Jul 9 1999;285(5425):248-251.
 140. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature.* Jul 11 2002;418(6894):191-195.
 141. Schiraldi M, Raucci A, Munoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. *The Journal of experimental medicine.* Feb 27 2012.
 142. Gaggar A, Rowe SM, Matthew H, Blalock JE. Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. *Open Respir Med J.* 2010;4:32-38.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
143. Mollinedo F, Borregaard N, Boxer LA. Novel trends in neutrophil structure, function and development. *Immunol Today*. Dec 1999;20(12):535-537.
 144. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat Rev Immunol*. Aug 2011;11(8):519-531.
 145. Painter RG, Bonvillain RW, Valentine VG, et al. The role of chloride anion and CFTR in killing of *Pseudomonas aeruginosa* by normal and CF neutrophils. *J Leukocyte Biol*. Jun 2008;83(6):1345-1353.
 146. Painter RG, Marrero L, Lombard GA, Valentine VG, Nauseef WM, Wang G. CFTR-mediated halide transport in phagosomes of human neutrophils. *J Leukocyte Biol*. May 2010;87(5):933-942.
 147. Painter RG, Valentine VG, Lanson NA, Jr., et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. *Biochemistry-US*. Aug 29 2006;45(34):10260-10269.
 148. Taggart C, Coakley RJ, Greally P, Canny G, O'Neill SJ, McElvaney NG. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. *Am J Physiol-Lung C*. Jan 2000;278(1):L33-L41.
 149. Brennan S, Cooper D, Sly PD. Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. *Thorax*. Jan 2001;56(1):62-64.
 150. Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. *Journal of Cystic Fibrosis*. Jan 2006;5(1):17-25.
 151. Kingma PS, Dimitriou S, Wooldridge JL, Karp CL. Cfr and Neutrophil Function: Our Children May Have the Answers. *Pediatr Pulmonol*. 2010:138-139.
 152. McKeon DJ, Cadwallader KA, Idris S, et al. Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation. *European Respiratory Journal*. Jun 2010;35(6):1264-1272.
 153. Mackarel AJ, Plant BJ, FitzGerald MX, O'Connor CM. Cystic fibrosis sputum stimulates CD18-independent neutrophil migration across endothelial cells. *Exp Lung Res*. May 2005;31(4):377-390.
 154. McKeon DJ, Condliffe AM, Cowburn AS, et al. Prolonged survival of neutrophils from patients with Delta F508 CFTR mutations. *Thorax*. Jul 2008;63(7):660-661.
 155. McKeon DJ, Cadwallader KA, Condliffe AM, Bilton D, Chilvers ER. The function and fate of neutrophils in cystic fibrosis. *Thorax*. Dec 1 2005;60:li93-li94.
 156. Moriceau S, Kantari C, Mocek J, et al. Coronin-1 is associated with neutrophil survival and is cleaved during apoptosis: potential implication in neutrophils from cystic fibrosis patients. *J Immunol*. Jun 1 2009;182(11):7254-7263.
 157. Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. *J Innate Immun*. 2010;2(3):260-266.
 158. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. *Eur Respir J*. Sep 2011;38(3):721-727.
 159. Gaggar A, Li Y, Weathington N, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. *Am J Physiol Lung Cell Mol Physiol*. Jul 2007;293(1):L96-L104.
 160. Hector A, Kormann MSD, Mack I, et al. The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease. *Plos One*. Sep 20 2011;6(9).

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
161. Hilliard JB, Konstan MW, Davis PB. Inflammatory mediators in CF patients. *Methods Mol Med.* 2002;70:409-431.
162. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. *J Immunol.* Jul 1 2005;175(1):404-412.
163. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. *Pediatr Pulmonol.* Mar 2005;39(3):224-232.
164. Sagel SD, Sontag MK, Accurso FJ. Relationship Between Antimicrobial Proteins and Airway Inflammation and Infection in Cystic Fibrosis. *Pediatr Pulmonol.* Apr 2009;44(4):402-409.
165. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg L, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. *J Pediatr-U.S.* Dec 2002;141(6):811-817.
166. Gray RD, Imrie M, Boyd AC, Innes JA, Porteous D, Greening AP. Development of sputum calprotectin as a biomarker of cystic fibrosis lung disease activity: Evidence from cross sectional and longitudinal studies. *Thorax.* Dec 2006;61:li34-li35.
167. Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a marker of inflammation in cystic fibrosis. *Arch Dis Child.* Feb 1996;74(2):136-139.
168. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. *Thorax.* Nov 2002;57(11):930-934.
169. Thomson E, Brennan S, Senthilmohan R, et al. Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. *Free Radical Bio Med.* Nov 15 2010;49(9):1354-1360.
170. Just J, Moog-Lutz C, Houzel-Charavel A, et al. Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis. *Febs Lett.* Sep 3 1999;457(3):437-440.
171. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. *Am J Resp Cell Mol.* Apr 1999;20(4):729-736.
172. Adib-Conquy M, Pedron T, Petit-Bertron AF, et al. Neutrophils in cystic fibrosis display a distinct gene expression pattern. *Mol Med.* Jan-Feb 2008;14(1-2):36-44.
173. McNally PG, Doyle M, Taggart C, et al. Protease anti-protease balance and innate defence proteins levels in the lungs of children with cystic fibrosis: Relationship to *P. aeruginosa* colonisation status. *Pediatr Pulmonol.* 2007:262-262.
174. Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. *Am J Respir Crit Care Med.* May 15 2005;171(10):1070-1076.
175. Moraes TJ, Plumb J, Martin R, et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. *Am J Resp Cell Mol.* Mar 2006;34(3):364-374.
176. Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and disease. *J Intern Med.* Jul 2010;268(1):25-34.
177. Downey DG, Martin SL, Dempster M, et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. *Pediatr Pulmonol.* Mar 2007;42(3):216-220.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
178. Reeves EP, Bergin DA, Fitzgerald S, et al. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. *J Cyst Fibros.* Oct 27 2011.
 179. Voglis S, Quinn K, Tullis E, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. *Am J Respir Crit Care Med.* Jul 15 2009;180(2):159-166.
 180. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature.* Oct 12 2000;407(6805):762-764.
 181. Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of *Pseudomonas aeruginosa* biofilm development: human F-actin and DNA as targets for therapy. *J Med Microbiol.* Apr 2009;58(Pt 4):492-502.
 182. Jesaitis AJ, Franklin MJ, Berglund D, et al. Compromised host defense on *Pseudomonas aeruginosa* biofilms: characterization of neutrophil and biofilm interactions. *J Immunol.* Oct 15 2003;171(8):4329-4339.
 183. Kharazmi A, Rechnitzer C, Schiotz PO, Jensen T, Baek L, Hoiby N. Priming of neutrophils for enhanced oxidative burst by sputum from cystic fibrosis patients with *Pseudomonas aeruginosa* infection. *Eur J Clin Invest.* Jun 1987;17(3):256-261.
 184. Kolpen M, Hansen CR, Bjarnsholt T, et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic *Pseudomonas aeruginosa* pneumonia in cystic fibrosis. *Thorax.* Jan 2010;65(1):57-62.
 185. Koller B, Kappler M, Latzin P, et al. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. *J Immunol.* Aug 15 2008;181(4):2753-2763.
 186. Usher LR, Lawson RA, Geary I, et al. Induction of neutrophil apoptosis by the *Pseudomonas aeruginosa* exotoxin pyocyanin: a potential mechanism of persistent infection. *J Immunol.* Feb 15 2002;168(4):1861-1868.
 187. Young RL, Malcolm KC, Kret JE, et al. Neutrophil Extracellular Trap (NET)-Mediated Killing of *Pseudomonas aeruginosa*: Evidence of Acquired Resistance within the CF Airway, Independent of CFTR. *Plos One.* Sep 1 2011;6(9).
 188. Dacheux D, Toussaint B, Richard M, Brochier G, Croize J, Attree I. *Pseudomonas aeruginosa* cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. *Infect Immun.* May 2000;68(5):2916-2924.
 189. Worlitzsch D, Herberth G, Ulrich M, Doring G. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. *Eur Respir J.* Feb 1998;11(2):377-383.
 190. Reynolds WF, Sermet-Gaudelus I, Gausson V, et al. Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease. *Mediators Inflamm.* 2006;2006(2):36735.
 191. Witko-Sarsat V, Allen RC, Paulais M, et al. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. *J Immunol.* Sep 15 1996;157(6):2728-2735.
 192. van der Vliet A, Cross CE. Phagocyte oxidants and nitric oxide in cystic fibrosis: new therapeutic targets? *Curr Opin Pulm Med.* Nov 2000;6(6):533-539.
 193. van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE. Oxidative stress in cystic fibrosis: does it occur and does it matter? *Adv Pharmacol.* 1997;38:491-513.

- 1 **194.** Tirouvanziam R. Neutrophilic inflammation as a major determinant in the
2 progression of cystic fibrosis. *Drug News Perspect.* Dec 2006;19(10):609-614.
- 3 **195.** Hayes E, Pohl K, McElvaney NG, Reeves EP. The Cystic Fibrosis Neutrophil: A
4 Specialized Yet Potentially Defective Cell. *Arch Immunol Ther Ex.* Apr
5 2011;59(2):97-112.
- 6 **196.** Downey GP. Is There a Primary Neutrophil Defect in Cf? *Pediatr Pulmonol.*
7 2011:163-164.
- 8 **197.** Hector A, Jonas F, Kappler M, Feilcke M, Hartl D, Griese M. Novel Method to
9 Process Cystic Fibrosis Sputum for Determination of Oxidative State. *Respiration.*
10 Dec 23 2009.
- 11 **198.** Tirouvanziam R, Gernez Y, Conrad CK, et al. Profound functional and signaling
12 changes in viable inflammatory neutrophils homing to cystic fibrosis airways.
13 *Proc Natl Acad Sci U S A.* Mar 18 2008;105(11):4335-4339.
- 14 **199.** Makam M, Diaz D, Laval J, et al. Activation of critical, host-induced, metabolic and
15 stress pathways marks neutrophil entry into cystic fibrosis lungs. *P Natl Acad Sci*
16 *USA.* Apr 7 2009;106(14):5779-5783.
- 17 **200.** Hartl D, Krauss-Etschmann S, Koller B, et al. Infiltrated neutrophils acquire novel
18 chemokine receptor expression and chemokine responsiveness in chronic
19 inflammatory lung diseases. *J Immunol.* Dec 1 2008;181(11):8053-8067.
- 20 **201.** Witko-Sarsat V, Sermet-Gaudelus I, Lenoir G, Descamps-Latscha B. Inflammation
21 and CFTR: might neutrophils be the key in cystic fibrosis? *Mediators Inflamm.*
22 1999;8(1):7-11.
- 23 **202.** Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill
24 bacteria. *Science.* Mar 5 2004;303(5663):1532-1535.
- 25 **203.** Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function:
26 from mechanisms to disease. *Annu Rev Immunol.* 2012;30:459-489.
- 27 **204.** Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons.
28 *Trends Immunol.* Nov 2009;30(11):513-521.
- 29 **205.** Manzenreiter R, Kienberger F, Marcos V, et al. Ultrastructural characterization of
30 cystic fibrosis sputum using atomic force and scanning electron microscopy. *J*
31 *Cyst Fibros.* Oct 11 2011.
- 32 **206.** Tolker-Nielsen T, Hoiby N. Extracellular DNA and F-actin as targets in antibiofilm
33 cystic fibrosis therapy. *Future Microbiol.* Aug 2009;4(6):645-647.
- 34 **207.** Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W.
35 DNA concentrations in BAL fluid of cystic fibrosis patients with early lung
36 disease: influence of treatment with dornase alpha. *Pediatr Pulmonol.* Jan
37 2005;39(1):1-4.
- 38 **208.** Perks B, Shute JK. DNA and actin bind and inhibit interleukin-8 function in cystic
39 fibrosis sputa: in vitro effects of mucolytics. *Am J Respir Crit Care Med.* Nov
40 2000;162(5):1767-1772.
- 41 **209.** Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ. Increased DNA
42 levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis.
43 *Am J Respir Crit Care Med.* Nov 1996;154(5):1426-1429.
- 44 **210.** Young RL, Malcolm KC, Kret JE, et al. Effective Pseudomonas Aeruginosa-Induced
45 Neutrophil Extracellular Trap Response by Normal & Cystic Fibrosis Neutrophils.
46 *Pediatr Pulmonol.* 2010:281-281.
- 47 **211.** McCormick A, Heesemann L, Wagener J, et al. NETs formed by human neutrophils
48 inhibit growth of the pathogenic mold *Aspergillus fumigatus*. *Microbes Infect.* Jul
49 16 2010.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 212.** Bonvillain RW, Painter RG, Adams DE, Viswanathan A, Lanson NA, Jr., Wang G. RNA interference against CFTR affects HL60-derived neutrophil microbicidal function. *Free Radic Biol Med.* Dec 15 2010;49(12):1872-1880.
- 213.** Phennicie RT, Sullivan MJ, Singer JT, Yoder JA, Kim CH. Specific resistance to *Pseudomonas aeruginosa* infection in zebrafish is mediated by the cystic fibrosis transmembrane conductance regulator. *Infect Immun.* Nov 2010;78(11):4542-4550.
- 214.** Su X, Looney MR, Su HE, Lee JW, Song Y, Matthay MA. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. *Inflammation research : official journal of the European Histamine Research Society ... [et al.].* Jul 2011;60(7):619-632.
- 215.** Pillay J, den Braber I, Vrisekoop N, et al. The in vivo half-life of human neutrophils Response. *Blood.* Jun 2 2011;117(22):6053-6054.
- 216.** Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. *Resp Res.* 2006;7:134.
- 217.** Bruscia EM, Zhang PX, Ferreira E, et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. *Am J Resp Cell Mol.* Mar 2009;40(3):295-304.
- 218.** Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. *Curr Opin Immunol.* Apr 2010;22(2):231-237.
- 219.** del Fresno C, Garcia-Rio F, Gomez-Pina V, et al. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. *J Immunol.* May 15 2009;182(10):6494-6507.
- 220.** Murphy BS, Bush HM, Sundareshan V, et al. Characterization of macrophage activation states in patients with cystic fibrosis. *J Cyst Fibros.* Sep 2010;9(5):314-322.
- 221.** Krysko O, Van Zele T, Claeys S, Bachert C. Comment on "potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients". *J Immunol.* Oct 15 2009;183(8):4831; author reply 4831-4832.
- 222.** Meyer M, Huaux F, Gavilanes X, et al. Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic Fibrosis. *Am J Resp Cell Mol.* Nov 2009;41(5):590-602.
- 223.** Bonfield TLH, C.A.; Drumm, M.L. The epithelial cell contingency: myeloid cells and inflammation resolution. *Pediatr Pulmonol.* 2011;33(33):272.
- 224.** Oceandy D, McMorran BJ, Smith SN, et al. Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. *Hum Mol Genet.* May 1 2002;11(9):1059-1067.
- 225.** Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth. *Sci Transl Med.* Apr 28 2010;2(29).
- 226.** Abdulrahman BA, Abu Khweek A, Akhter A, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by *Burkholderia cenocepacia* in a model of cystic fibrosis. *Autophagy.* Nov 2011;7(11):1359-1370.
- 227.** Deriy LV, Gomez EA, Zhang GP, et al. Disease-causing Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Determine the Functional Responses of Alveolar Macrophages. *J Biol Chem.* Dec 18 2009;284(51):35926-35938.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 228.** Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. *Nat Cell Biol.* Sep 2006;8(9):933-944.
- 229.** Radtke AL, Anderson KL, Davis MJ, DiMagno MJ, Swanson JA, O'Riordan MX. *Listeria monocytogenes* exploits cystic fibrosis transmembrane conductance regulator (CFTR) to escape the phagosome. *P Natl Acad Sci USA.* Jan 25 2011;108(4):1633-1638.
- 230.** Del Porto P, Cifani N, Guarnieri S, et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against *Pseudomonas aeruginosa*. *Plos One.* 2011;6(5):e19970.
- 231.** Zaman MM, Gelrud A, Junaidi O, et al. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. *Clin Diagn Lab Immun.* Sep 2004;11(5):819-824.
- 232.** Bruscia EM, Zhang PX, Satoh A, et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. *J Immunol.* Jun 15 2011;186(12):6990-6998.
- 233.** Thomas GR, Costelloe EA, Lunn DP, et al. G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages. *J Immunol.* Apr 1 2000;164(7):3870-3877.
- 234.** Andersson C, Zaman MM, Jones AB, Freedman SD. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. *Journal of Cystic Fibrosis.* Jan 2008;7(1):68-78.
- 235.** Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the Cystic-Fibrosis Transmembrane Conductance Regulator Gene in Cells of Nonepithelial Origin. *Nucleic Acids Res.* Oct 11 1991;19(19):5417-5423.
- 236.** Sorio C, Buffelli M, Angiari C, et al. Defective CFTR Expression and Function Are Detectable in Blood Monocytes: Development of a New Blood Test for Cystic Fibrosis. *Plos One.* Jul 21 2011;6(7).
- 237.** Haggie PM, Verkman AS. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. *The Journal of biological chemistry.* Oct 26 2007;282(43):31422-31428.
- 238.** Haggie PM. Does the Ph of Intracellular Organelles Differ in Cf Cells? *Pediatr Pulmonol.* 2009:117-117.
- 239.** Barriere H, Bagdany M, Bossard F, et al. Revisiting the Role of Cftr and Counterion Permeability in the Ph Regulation of Endolysosomes and Phagosomes. *Pediatr Pulmonol.* 2009:221-221.
- 240.** del Campo R, Martinez E, del Fresno C, et al. Translocated LPS might cause endotoxin tolerance in circulating monocytes of Cystic Fibrosis patients. *Plos One.* 2011;6(12):e29577.
- 241.** del Fresno C, Gomez-Pina V, Lores V, et al. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. *Plos One.* 2008;3(7):e2667.
- 242.** Srivastava M, Jung S, Wilhelm J, et al. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. *J Immunol.* Aug 1 2005;175(3):1884-1893.
- 243.** Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. *Chest.* Jun 2006;129(6):1673-1682.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
244. Watt AP, Courtney J, Moore J, Ennis M, Elborn JS. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. *Thorax*. Aug 2005;60(8):659-664.
 245. Vandivier RW, Richens TR, Horstmann SA, et al. Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. *Am J Physiol Lung Cell Mol Physiol*. Oct 2009;297(4):L677-686.
 246. Vandivier RW, Fadok VA, Ogden CA, et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. *Chest*. Mar 2002;121(3 Suppl):89S.
 247. Vandivier RW, Fadok VA, Hoffmann PR, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. *The Journal of clinical investigation*. Mar 2002;109(5):661-670.
 248. Xu YQ, Tertilt C, Krause A, Quadri LEN, Crystal RG, Worgall S. Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells. *Resp Res*. Apr 3 2009;10.
 249. Xu Y, Krause A, Wu W, Joh J, Limberis MP, Stefan W. Characterization of Pulmonary Dendritic Cells in the Lungs of Cystic Fibrosis Mice Following *Pseudomonas Aeruginosa* Infection. *Pediatr Pulmonol*. 2009:255-255.
 250. Roghanian A, Drost EM, MacNee W, Howie SEM, Sallenave JM. Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. *Am J Respir Crit Care Med*. Dec 1 2006;174(11):1189-1198.
 251. Regamey N, Tsartsali L, Hilliard TN, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. *Thorax*. Oct 18 2011.
 252. Schuster M, Tschernig T, Krug N, Pabst R. Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat. *Am J Respir Crit Care Med*. Feb 2000;161(2):558-566.
 253. Tschernig T, Boeke K, Steinhoff G, Wonigeit K, Pabst R, Westermann J. The lung as a source and a target organ for T- and B-lymphocytes. *Am J Resp Cell Mol*. Oct 1997;17(4):414-421.
 254. Pabst R, Tschernig T. Lymphocytes in the Lung - an Often Neglected Cell - Numbers, Characterization and Compartmentalization. *Anat Embryol*. Oct 1995;192(4):293-299.
 255. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. *Microbes Infect*. Apr 2009;11(5):625-630.
 256. Aujla SJ, Dubin PJ, Kolls JK. Interleukin-17 in pulmonary host defense. *Exp Lung Res*. Dec 2007;33(10):507-518.
 257. Kuchroo V, Korn T, Bettelli E, et al. Interplay between pathogenic effector Th17 and regulatory T cells in autoimmunity and tissue inflammation. *Clin Exp Rheumatol*. Jul-Aug 2008;26(4):714-714.
 258. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*. Feb 2006;24(2):179-189.
 259. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. *Immunol Rev*. Jun 2008;223:87-113.
 260. Aujla SJ, Chan YR, Zheng MQ, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. *Nat Med*. Mar 2008;14(3):275-281.
 261. Aujla SJ, Kolls JK. IL-22: A critical mediator in mucosal host defense. *J Mol Med-Jmm*. May 2009;87(5):451-454.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
262. Dubin PJ, Kolls JK. IL-17 in Cystic Fibrosis: More Than Just Th17 Cells. *Am J Respir Crit Care Med.* Jul 15 2011;184(2):155-157.
263. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? *Inflamm Res.* Jun 2007;56(6):221-227.
264. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid *Pseudomonas aeruginosa* lung infection in mice. *Am J Physiol-Lung C.* Feb 2007;292(2):L519-L528.
265. Dubin PJ, Martz A, Eisenstatt JR, Fox MD, Logar A, Kolls JK. Interleukin-23-Mediated Inflammation in *Pseudomonas aeruginosa* Pulmonary Infection. *Infect Immun.* Jan 2012;80(1):398-409.
266. Brodli M, Lordan J, Ward C. Can cells other than Th17 lymphocytes be important sources of IL-17 in the lungs? *Thorax.* Dec 2011;66(12):1096-1096.
267. Brodli M, McKean MC, Johnson GE, et al. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. *European Respiratory Journal.* Jun 2011;37(6):1378-1385.
268. Decraene A, Willems-Widyastuti A, Kasran A, De Boeck K, Bullens DM, Dupont LJ. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients. *Resp Res.* Dec 10 2010;11.
269. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 Pathway in Cystic Fibrosis Lung Disease. *Am J Respir Crit Care Med.* Jul 15 2011;184(2):252-258.
270. Moss RB. Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. *Clin Exp Immunol.* Mar 2004;135(3):358-360.
271. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. *Clin Exp Immunol.* Jun 2000;120(3):518-525.
272. Conese M. Cystic fibrosis and the innate immune system: therapeutic implications. *Endocr Metab Immune Disord Drug Targets.* Mar 2011;11(1):8-22.
273. Davies JC, Johnson M, Booth C, et al. Age-specific effect of the cystic fibrosis modifier gene, MBL-2. *Thorax.* Dec 2002;57.
274. Davies JC, Turner MW, Klein N, Grp LMCS. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. *European Respiratory Journal.* Nov 2004;24(5):798-804.
275. McDougal KE, Green DM, Vanscoy LL, et al. Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. *Eur J Hum Genet.* Jun 2010;18(6):680-684.
276. Taylor C, Huang B, Dorfman R, et al. The effect of MBL2 gene variants on the age of first infection in Cystic Fibrosis (CF) patients is modified by TGF beta 1 gene variants. *Genet Epidemiol.* Sep 2007;31(6):646-646.
277. Weersink FJ, Frakking FN, Brouwer N, et al. Mannose-binding lectin (MBL) in cystic fibrosis (CF). *Pediatr Pulmonol.* 2007:271-272.
278. Zielenski JS, Pereira L, Culp L, Raskin S, Tsui LC. Analysis of mannose binding lectin (MBL) haplotypes in a large cohort of cystic fibrosis patients. *Am J Hum Genet.* Oct 2001;69(4):650-650.
279. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. *N Engl J Med.* Oct 6 2005;353(14):1443-1453.
280. de Faria EJ, de Faria ICJ, Ribeiro JD, Ribeiro AF, Liessel G, Bertuzzo CS. Association of MBL2, TGF-beta 1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. *J Bras Pneumol.* Apr 2009;35(4):334-342.
281. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. *Nature.* Apr 23 2009;458(7241):1039-1042.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 282.** Drumm ML. Modifier genes and variation in cystic fibrosis. *Resp Res.* 2001;2(3):125-128.
- 283.** Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nat Genet.* Jun 2011;43(6):539-546.
- 284.** Banner KH, De Jonge H, Elborn S, et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. *J Cyst Fibros.* Jan 2009;8(1):1-8.
- 285.** Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. *Respir Care.* May 2009;54(5):595-605.
- 286.** Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. *Am J Resp Cell Mol.* Oct 2004;31(4):377-381.

Figure 1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)

